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 Chapter 1: General Introduction 
 
Prostate cancer is the second most common cancer in men worldwide, with an incidence of 1.1 million in 
2012 [1]. In the Netherlands, prostate cancer is the most common cancer among men, with an incidence 
of 11,683 in 2017. As age is the most important risk factor for the development of prostate cancer and 
since the population is ageing, the incidence in the Netherlands is expected to increase in the near future 
and beyond [2] [3]. 
Taking this increase into account, treatment of prostate cancer will require extra attention in the near 
future. The decision-making process in prostate cancer treatment has traditionally been based upon two 
outcomes: the level of tumour control (and or survival) and the probability of developing side effects for a 
certain treatment. Late radiation-induced side effects are particularly relevant clinically, and these may 
have an impact on quality of life for prostate cancer survivors. 
 
Figure 1: Incidence of prostate cancer in the Netherlands. www.cijfersoverkanker.nl 
Prostate cancer treatment 
Curatively intended prostate cancer treatment may involve radical prostatectomy, brachytherapy or 
external beam radiotherapy with or without adjuvant hormonal therapy. Evidence for which treatment is 
best has not been established by randomized trials in which these treatment modalities have been directly 
compared [4]. Treatment decisions are commonly based on the assumption that cure rates obtained with 
the different modalities are similar in low-risk disease (T1c-T2a, Gleason score <7, iPSA <10 ng/mL) 
irrespective of treatment modality. The only randomized trial on the efficiency of prostate cancer 
radiotherapy concerned patients with localized and mainly locally advanced prostate cancer (outside 
prostatic capsule) [5]. A significant reduction was found in prostate cancer specific mortality from 23.9% 
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Prostatectomy, external beam radiotherapy and brachytherapy all offer the opportunity to decrease 
prostate cancer related death [4]. The evidence for neo-adjuvant hormonal therapy regarding tumour 
control is present for locally advanced prostate cancer [6]. Recently, research has shown a significant 
improvement in biochemical disease-free survival (HR 0.52) for intermediate (T2b-c, of Gleason score 7) 
and high risk (T3, of Gleason score >7, or iPSA >20 ng/mL) prostate cancer patients treated with adjuvant 
hormonal therapy [7]. Finally, dose escalation in external beam radiotherapy has resulted in increased 
biochemical tumour control [8]. However, the down side of target dose escalation is an increase of dose 
to organs-at-risk adjacent to the prostate consequently, more radiation-induced side effects.  
Radiation induced side effects 
As the prostate is adjacent to the bladder and anorectum, irradiating the prostate results in unintended 
co-irradiation of these organs at risk. Consequently, side effects may occur, which are traditionally divided 
into gastrointestinal and genitourinary side effects. Gastrointestinal side effects include rectal bleeding, 
faecal incontinence, diarrhoea, increase in stool frequency, mucus loss and rectal pain. Genitourinary side 
effects include urinary incontinence, haematuria, and frequent micturition, pain during voiding and sexual 
dysfunction. From a clinical point of view, rectal bleeding is mostly considered of high importance, as it 
may require transfusions, although the need for these is rare [9]. From a patient’s perspective, other side 
effects such as urinary or faecal incontinence may be more important as these may have a marked impact 
on daily functioning.  
Radiation-induced side effects can be assessed using different grading systems [10]: The Radiation Therapy 
Oncology Group (RTOG) [11], Late Effects of Normal Tissue Subjective, Objective, Medical management 
and Analytic evaluation of injury (LENT-SOMA) [12] and Common Terminology Criteria for adverse events 
(CTCAE) [13]. The RTOG and CTCAE are the most commonly used grading systems in prostate cancer 
treatment. The CTCAE grading system provides an organ-specific list with physician-rated measurements 
for each specific complaint and accompanying grading, while the RTOG grading provides only a more 
general classification for some endpoints of prostate cancer treatment. This is the main reason for the 
application of the CTCAE toxicity scoring system at our department in the standardized follow-up program 
(SFP) for prostate cancer patients. 
To reduce the risk of both gastrointestinal and genitourinary side effects, information on the relation 
between complication risk and dose-volume parameters of bladder and anorectum is crucial [9]. The 
relationship between 3D dose distributions and the risk of a given side effect is generally described by 
Normal Tissue Complication Probability (NTCP) models. These may contain dose-volume parameters and 
other baseline characteristics such as patient- tumour- and treatment-related features.  NTCP models can 
be used for different purposes: They can be used to estimate the risk of developing a certain complication 
for a given patient based on the dose distribution and other predictors included in the model [14]; they 
can also be used to guide treatment planning optimization; and they can be used to identify which patients 
may benefit most from new and more complex radiation delivery techniques, such as protons [15].  
In the Netherlands, proton therapy is now gradually introduced for different tumour sites. Selection of 
patients is based on the so-called model-based approach [14]. In this approach, the best possible photon 
plan is compared with the best possible proton plan to calculate the dose distributions in the most relevant 
 
organs at risk and subsequently to assess the difference in dose between the two modalities (∆Dose). In 
addition, to determine the clinical relevance of ∆Dose, NTCP-models are used to translate ∆Dose into 
∆NTCP, i.e. the expected benefit in terms of the risk reduction for a given side effect. When this is done 
for more than one radiation-induced side effect, a so-called ∆NTCP-profile can be produced, which can be 
considered as a biomarker for the expected benefit of protons compared to photons for each individual 
patient. In the Netherlands, a consensus has been reached on the ∆NTCP-thresholds depending on the 
grading of the toxicities. For grade 2, 3 and 4/5, ∆NTCP-thresholds should be ≥10%, ≥5% and ≥2%, 
respectively, to quality for proton therapy. However, a national indication protocol to select prostate 
cancer patients for proton therapy is currently not yet available. 
Unmet needs 
One of the requirements of the model-based approach is the availability of high quality multivariable 
NTCP-models in order to be able to translate ∆Dose into a ∆NTCP-profile. To be suitable for model-based 
selection, NTCP-models should meet a number of important quality criteria, including:  
1. Toxicity scoring should be done prospectively, as retrospective assessment generally results in an 
underestimation of radiation-induced toxicity; 
2. The number of patients and events should be sufficient; 
3. NTCP-models should be multivariable, not only including dose-volume parameters but also other 
characteristics that are independent predictors for toxicity or may be confounders or effect 
modulaters for the dose-volume factors; 
4. There should be a clinical decision rule, i.e. an equation, nomogram or graph that can be used to 
calculate NTCP-values for individual patients based on the dose distributions and other pre-treatment 
predictors; 
5. The quality of the model in terms of model performance should be assessed (e.g. discrimination and 
callibration); 
6. Internal validation should be performed to correct for overfitting; 
7. Preferably external validation should be done in an independent patients cohort to test the 
generalisibility of the model. 
When we started this project, the number of published NTCP-models did not meet most of these criteria. 
The department of Radiation Oncology at UMCG has a long tradition of prospective assessment of 
radiation-induced toxicity and quality of life in different tumour sites, including of prostate cancer patients. 
The data from this prospective data registration program offers unique opportunities to develop 
multivariable NTCP-models and to investigate quality of life among patients treated with radiotherapy.   
 
Outline of this thesis 
The aims of this thesis were to investigate the course of quality of life among prostate cancer patients 
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ultimately to develop multivariable NTCP-models for prostate cancer patients treated with definitive 
radiotherapy. 
Chapter 2 presents the difference in quality of life between prostate cancer survivors and a normative 
cohort. Using a mixed model statistical analysis, the longitudinal effects of radiotherapy can be appraised. 
In this case-control study, special attention was given to comorbidity, which is present in the majority of 
the elderly population. 
Chapter 3 describes the impact of genitourinary and gastrointestinal side effects on quality of life. Different 
aspects of quality of life were analysed by means of a multivariate analysis of variance (MANOVA). In this 
analysis, functioning scales and relevant symptom scales were analysed in one single analysis, taking into 
account the interdependency of the scales.  
Chapter 4 reports on the relationship between dose volume parameters of the anorectum and gastro-
intestinal side effects. In contrast to current literature on prostate cancer irradiation, in this study different 
unique dose-volume parameters were related to different unique endpoints. The anorectum was divided 
into smaller substructures and additional Regions of Interest (ROI) were delineated in order to estimate 
the best prognostic model for each endpoint. 
In chapter 5, a similar analysis was performed for genitourinary side effects by dividing the bladder into 
smaller substructures. Finally, for each endpoint a multivariable NTCP model was estimated. In these 
studies, a data-driven approach was used to build models, whereas knowledge-based models are another 
commonly used option to build models.  
The findings of this thesis are discussed and summarized in Chapter 6. A Dutch translation of the summary 
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To investigate the course of quality of life (QoL) among prostate cancer patients treated with external 
beam radiotherapy and to compare the results with QoL of a normal age-matched reference population. 
Patients and methods 
The study population was composed of 227 prostate cancer patients, treated with radiotherapy. The 
EORTC QLQ-C30 was used to assess QoL before radiotherapy and six months, one year, two years and 
three years after completion of radiotherapy. Mixed model analyses were used to investigate 
longitudinal changes in QoL. QoL of prostate cancer patients was compared to that of a normative cohort 
using a multivariate analysis of covariance. 
Results 
A significant decline in QoL was observed after radiotherapy (p < 0.001). The addition of hormonal 
therapy to radiotherapy was associated with a lower level of role functioning. Patients with coronary 
heart disease and or chronic obstructive pulmonary disease or asthma had a significantly worse course in 
QoL. Although statistically significant, all differences were classified as small or trivial. 
Conclusion 
Prostate cancer patients experience a small worsening of QoL as compared with baseline and as 
compared with a normal reference population. As co-morbidity modulates patients’ post-treatment QoL, 







Quality of life (QoL) among prostate cancer patients is an important outcome measure of therapy, 
providing relevant information on how patients experience their functioning in daily life after treatment. 
Although high survival rates after curative radiotherapy have been reported [1], side effects like fecal or 
urinary incontinence may occur as a result of prostate radiotherapy. As a substantial proportion of prostate 
cancer patients report these side effects during follow-up [1–4], QoL may be transiently or permanently 
reduced.  
QoL after therapy may not only be affected by the development of side effects, but also by baseline 
measures of QoL, e.g., due to the presence of co-morbidity. A previous study showed that as much as 53% 
of the population aged 55 years and older had at least onemild or severe chronic condition [5]. The 
question arises as to whether co-morbidity plays an important role in the changes of QoL after treatment 
among prostate cancer patients. Although QoL has been measured widely among prostate cancer patients 
[6–8], baseline measures of QoL and the effect of co-morbidity have not been consistently taken into 
account. 
Interpretation of the results of QoL studies is challenging and could be facilitated by comparing 
the results with QoL measured in the general population in order to determine the additional functional 
impairment and symptom burden associated with prostate cancer and its treatment [9]. Normative data 
not only enables comparing QoL scores of prostate cancer patients against those obtained in the 
normative population, but also offers the opportunity to analyze the impact of covariates such as age and 
co-morbidity [10]. 
 Therefore, the objective of the current study was twofold. The primary objective was to 
investigate to what extent QoL changes after completion of curative radiotherapy among prostate cancer 
patients, with special attention to the influence of baseline QoL and co-morbidity. The second objective 
was to investigate to what extent QoL of prostate cancer patients differs from that of a normal reference 
population. 
  
Patients and methods 
 
Study design, patient and normative cohort selection, treatment  
The study population of this prospective cohort study was composed of 227 patients with localized 
or locally advanced prostate cancer. All patients were treated at the University Medical Center Groningen 
and were originally included in two multicenter prospective randomized studies. Ninety-nine patients 
were included in the European Organization for Research and Treatment of Cancer (EORTC) 22961 trial 
and 128 patients in the EORTC 22991 trial. The EORTC 22961 trial started in 1997 and was designed to 
evaluate the influence of adjuvant hormonal treatment with an LHRH (luteinizing-hormone-releasing 
hormone) analog in patients with locally advanced prostate cancer treated with 3D-CRT. The EORTC 22961 
protocol included patients with non-metastatic T1c- T2bN1-2/pN1-2 (after pelvic lymphadenectomy) or 
T2c-T4N0-2 (UICC 1992 TNM classification) histologically confirmed adenocarcinoma of the prostate. 
Quality of life among prostate cancer patients: 
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Patients in the long arm (three years) received combined androgen blockade for a period of three years, 
while patients in the short arm received combined androgen blockade for a period of only six months [11].  
In the EORTC 22991 trial, radiotherapy alone, either 3D-CRT or IMRT, was compared with the same 
radiotherapy combined with adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic 
carcinoma. Patients in the adjuvant hormonal arm started hormonal treatment one week before 
radiotherapy with antiandrogens each day for a period of one month and additionally two injections of 
LHRH during the next six months [12]. For the purpose of the current analysis, only patients biochemically 
failure free at the time of QoL assessments were eligible.  
All patients were treated with external beam radiotherapy. A planning CT of all patients was 
obtained in treatment position (supine). The clinical target volume (CTV) was defined as the prostate and 
the seminal vesicles. Radiotherapy was delivered with linear accelerators using photons with either 3-
dimensional conformalradiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT). Patients were 
treated 5 times a week to a total dose of 70 Gy (3D-CRT) or 78 Gy (IMRT). 
The patient cohort was compared to a normative cohort of male individuals from the PROFILES 
study [9]. QoL normative data were obtained from the Health and Health Complaints project from 
CentERdata. The CentERpanel cohort represents the Dutch-speaking population in the Netherlands, 
including those without Internet access. From this panel a normative cohort of 519 men was selected, 
resulting in an age matched comparison between the patient cohort and the normative cohort. 
 
Quality of life assessment 
QoL was measured by means of the EORTC Quality of life Questionnaire C30 (EORTC QLQ-C30) 
[13] prior to the start of radiotherapy and subsequently at 6, 12, 24 and 36 months after completion of 
radiotherapy. The current analysis covered five QoL scales that were considered to be most likely affected 
by therapy and/or comorbidity, including global quality of life, physical functioning, social functioning, 
emotional functioning and role functioning. In addition, six symptom scales were analyzed, including 
fatigue, pain, dyspnea, insomnia, constipation and diahrroea. QoL-scores were linearly converted to a scale 
ranging from 0 to 100, according to EORTC guidelines. For the functional and global health status/quality 
of life scales, higher scores represent better levels of functioning. For the symptom scales, higher scores 
represent a greater degree of symptoms. 
 
Statistics 
Changes in QoL before and after treatment were estimated by means of a mixed model analysis. 
The first advantage of a mixed model analysis over a standard analysis of variances (ANOVA) is that it takes 
into account variability between patients’ (baseline) scores. Secondly, a mixed model ANOVA can deal 
better with missing values than the standard ANOVA model. Using a standard ANOVA model, one or more 
missing observations in one patient result in a complete loss of all data of that particular patient, while 
using the mixed model approach only the missing observations are lost. Other factors included in the 
model were adjuvant hormonal therapy, radiotherapy technique and co-morbidity.  
To investigate the clinical relevance of the longitudinal differences, the effect sizes were 
categorized as proposed in a meta-analysis by Cocks [14] into trivial, small, medium and large differences 
per scale. To investigate the differences between prostate cancer patients 3 years after treatment and the 
 
normative cohort a multivariate analysis of covariance (MANCOVA) was used. Unbalanced distribution of 
patient characteristics (Table 1) was accounted for by means of the addition of covariates into the model. 
To investigate the clinical relevance of the differences with the normative comparison, the effect sizes 
were categorized as proposed by Cocks [15]: trivial, small, medium or large difference per scale. A p-value 
of 0.05 was considered to be statistically significant.  
 
Table 1: Patients and normative cohort characteristics 
          
    
Patients 
(%)   Norm (%) 
      
N= 
227   N= 519 
Heart disease   49 (22)   97 (19)   
COPD and asthma   24 (11)   46 (9)   
Hypertension   62 (27)   176 (34) * 
Stroke   5 (2)   4 (1)   
Diabetes   21 (9)   47 (9)   
Peptic ulcer   4 (2)   8 (2)   
Kidney disease   4 (2)   9 (2)   
Liver disease   0 (0)   2 (0.4)   
Thyroid disease   3 (1)   6 (1)   
Age ≤70 134 (59)   360 (69) * 
                
Tumor classification               
  T1 85 (37)         
  T2 68 (30)         
  T3 74 (33)         
PSA               
  < 10 50 (22)         
  10-20 97 (43)         
  20-40 60 (26)         
  >40 20 (9)         
Adjuvant treatment               
  Radiotherapy only 71 (31)         
  
Radiotherapy and hormonal 
therapy 156 (69)         
Radiotherapy 
Modality               
  IMRT 70 (31)         
  3D-CRT 157 (69)         
                
* Statistically significant at 0.05 using Fisher exact test       
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Sample description and compliance 
At baseline, 200 out of the 227 patients completed the QoL questionnaire. The compliance rate 
six months after treatment was 95% (210 out of 221 patients alive), 96% after one year (208 out of 216 
patients alive), 95% after two years (202 out of 213 patients alive) and 88% three years after radiotherapy 
(184 out of 209 patients alive). The majority of patients was treated with adjuvant hormonal therapy and 
3D-CRT. The median age was 70 years (range 53–85). 
Baseline patient characteristics and normative cohort characteristics are listed in Table 1. The 
prevalence of co-morbidities did not differ significantly between the patients and the normative cohort, 
except for hypertension. Although the patient and normative cohort had the same age range, the average 
age of the prostate cancer patient cohort (69.2)wassignificantly higher than that of the normative cohort 
(66.6, p < 0.001). This imbalance was accounted for by adding age as a covariate into the statistical analysis. 
 
Longitudinal effects in the patient cohort 
The mixed model analysis revealed that in general, patients’ post-treatment QoL was worse as 
compared to pre-treatment QoL (Figs. 1 and 2). Post-treatment global QoL and emotional functioning did 
not differ from baseline (Table 2). A minimal but statistically significant decrease was observed for physical 
functioning. The scores of role- and social functioning decreased after treatment and reached a plateau at 
6 months after radiotherapy. Five out of six symptom scales changed relative to baseline. Fatigue, dyspnea 
and insomnia increased after treatment with maximum levels of impairment at six months after treatment. 
The level of constipation and diarrhea after radiotherapy increased compared to baseline in particular at 
one year after radiotherapy. Although the pvalues for time effects were statistically significant, the 
absolute differences were relatively small. The maximum mean difference was 8.02 for insomnia. Using 
the criteria from Cocks [14] for clinical relevance, all longitudinal differences observed were considered 
trivial or small. 
No differences in QoL were found between 3D-CRT and IMRT patients. QoL was significantly 
affected by two co-morbid conditions. First ‘‘COPD and asthma’’, which affected global quality of life, 
physical-, role- and social functioning (p < 0.003). These patients also reported more fatigue, dyspnea and 
insomnia (p < 0.02). Second, coronary heart disease, which affected global quality of life, role- and social 
function (p < 0.03). Additionally these patients reported more dyspnea (p < 0.01). Adjuvant hormonal 
treatment affected both physical functioning (p < 0.001) and constipation (p = 0.043). Apart from these 
main effects, three significant interaction terms were found, indicating that some patient or treatment 
characteristics affected the course of QoL after treatment (Fig. 3a). First, patients treated with hormonal 
therapy had worse role functioning after treatment than patients without hormonal treatment. For 
patients treated with short-term adjuvant hormonal therapy, a decline in role functioning was noted at six 
months after radiotherapy. For patients with long-term hormonal therapy a similar decline was observed 
at 6 months after radiotherapy, followed by a further deterioration at 12 months after radiotherapy. 
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Figure 1: Mean EORTC QLQ-C30 functioning scale scores of prostate cancer patients relative to the normative cohort: 
higher scores represent a better level of functioning   
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Figure 2: Mean EORTC QLQ-C30 symptom scale scores of prostate cancer patients relative to the normative cohort: 
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Figure 2: Mean EORTC QLQ-C30 symptom scale scores of prostate cancer patients relative to the normative cohort: 







































































radiotherapy as compared to patients treated without hormonal treatment. Second, patients with COPD 
or asthma did significantly worse on role functioning than patients without this co-morbid disease (Fig. 
3b), especially 12 months after radiotherapy patients with COPD or asthma had a lower role functioning 
than patients without this co-morbidity. Finally, the patients with coronary heart disease did significantly 
worse with regard to social functioning compared to patients without coronary heart disease (Fig. 3c).  
 
Comparison with the normative cohort 
Three factors were entered into the MANCOVA model as covariates, as they significantly affected 
QoL including ‘‘age’’, ‘‘CHD’’ and ‘‘COPD or asthma’’ (Table 3). This analysis revealed a statistically 
significant difference in QoL between the prostate cancer patient cohort (3 years after treatment) and the 
normative cohort. ‘‘CHD’’ and ‘‘COPD and asthma’’ also significantly affected QoL. 
To get insight into which QoL scales were affected most, we focused on the differences between 
the two groups on every single scale. Prostate cancer patients did significantly worse on three out of five 
functioning scales as compared to the normative cohort, i.e., role-, emotional- and social functioning. 
Prostate cancer patients also reported more dyspnea and insomnia than males from the normative cohort. 
The clinical relevance of these differences was classified as trivial or small, except for dyspnea, which was 
classified as a medium effect. 
 
Discussion 
The main objective of this study was to determine the course of QoL of prostate cancer patients 
after curative radiotherapy. Our study shows that QoL deteriorates most during the first six months after 
treatment and then remains more or less unchanged up to three years after completion of radiotherapy. 
In addition, we found that the QoL of prostate cancer patients three years after radiotherapy is worse than 
QoL of males from a normative population. Although both longitudinal and population differences show 
statistical significance, the clinical relevance of these differences was small and should be considered 
trivial. 
The main strengths of the current study are the baseline measurements, the long-term follow-up, 
the high compliance rates, the population-based design, and the adjustment for comorbidities. It is 
important to include baseline levels of QoL, as the course of QoL over time may depend on baseline scores 
[7]. In another study small, but non-significant deteriorations in patients’ QoL, as measured by the SF-36 
were found [16]. The cross-sectional design of that study required longitudinal confirmation to account 
for differences in baseline measurements between patients. A proxy for baseline measurements of QoL is 
to ask patients to recall their QoL at baseline [17]. However, prostate cancer patients tend to remember 
their baseline QoL as being better than it actually was [18], indicating that an actual assessment of QoL at 
baseline is necessary. With the inclusion of actual baseline measurements, the current study showed that 
QoL among prostate cancer patients indeed deteriorated over time, but also that these differences were 
relatively small and have little clinical importance. 
Two other studies [7–8] covered patients with a maximum follow-up time of two years, while 
Pardo [19] and Hoskin [20] analyzed the QoL up to 3 and up to 10 years, respectively. The question may 
arise as to whether 36 months is an adequate follow-up time in longitudinal prostate cancer research. As 
late radiation-induced side effects occur or progress further over time [3] it may be important to assess 
 
QoL after two years, in order to be able to account for the possible effect of these side effects on QoL. In 
accordance with the outcome of a large randomized trial [21], the current study shows that quality of life 
is lower in the first 6 months after treatment and remains relatively unchanged up to three years after 
radiotherapy. 
As the compliance rates in the current study are high, the risk of selection bias as a consequence 
of missing data is small. However, exclusion of patients with biochemical failure prohibits the results to be 
generalized to all prostate cancer patients treated with radiotherapy. In this regard, it should be stressed 
that 35% of the patients with biochemical failure will develop metastatic disease within 8 years from the 
time of prostate-specific antigen elevation. This elevation may cause significant anxiety for patients which 
negatively affects QoL [22]. 
The population-based design of the present study not only enabled comparison of the QoL scores 
of patients against those obtained in the normative population, but also offered the opportunity to analyze 
the impact of covariates such as age and comorbidities. According to recommendations defined by Crosby 
[23], anchoring patient data to normative data indicates whether the differences before and after 
treatment are large, relative to a normative population. As both longitudinal differences and normative 
differences were small, our conclusion is supported on two fronts: a post-treatment to baseline contrast 
and a posttreatment to norm contrast. Co-morbidities significantly affected QoL of prostate cancer 
patients, which is in line with results obtained in other patient groups [9,24–25]. As prostate cancer is a 
malignant disease predominantly found among elderly patients and because the incidence of co-morbidity 
increases with age, it is especially important to account for this potential confounder when analyzing QoL 
among prostate cancer patients. However, in recent studies reporting on QoL after radiotherapy [6–8] the 
possible impact of co-morbidity had not been taken into account. As co-morbidities were retrospectively 
scored in the current research, an underestimation of the incidence of co-morbidities is possible. Despite 
this limitation, our study shows interesting findings concerning co-morbidities. That is ‘‘COPD and asthma’’ 
and ‘‘coronary heart disease’’ significantly affect role- and social functioning among prostate cancer 
patients. This is in accordance with two studies on the impact of co-morbidities on QoL of prostate cancer 
patients [26–28]. To explain the falling course in QoL of patients with COPD, we retrospectively analyzed 
these patients’ doctor visits to other departments. There, we observed an increase in COPD exacerbations 
around twelve months after radiotherapy and additionally, an increase of the impact of dyspnea on role 
functioning. This indicates that COPD patients may be bothered more by dyspnea at twelve months than 
at baseline, finally resulting in a decreased role functioning. Future research should emphasize more on 
this synergistic effect of COPD and radiotherapy on QoL in order to prevent a further decline in QoL among 
males with these risk factors. 
Two issues in this research require extra attention. First, as QoL assessment has an inherent 
subjective nature, possible changes of patients’ internal standards, changing values and conceptualization 
of QoL may well have an effect on patients’ scoring of QoL. This phenomenon is referred to as response 
shift, which may explain the relatively small changes in QoL [29]. A subset of patients may also rate their 
HRQoL as always good (or bad) and always improving (or declining), reflecting a dispositional optimism (or 
pessimism). This general methodological concern may be a possible limitation in determining a minimally 
important difference in change score in al HRQoL studies [30]. Another important issue is the course of 
patients’ sexual functioning. Unfortunately, sexual functioning was not assessed in our study. The odds of 
erectile dysfunction increase after radiotherapy [31,32] and hormonal therapy has an additional negative 
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radiotherapy as compared to patients treated without hormonal treatment. Second, patients with COPD 
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functioning. This indicates that COPD patients may be bothered more by dyspnea at twelve months than 
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patients’ sexual functioning. Unfortunately, sexual functioning was not assessed in our study. The odds of 




impact on sexual functioning [33]. Therefore, we recommend further longitudinal studies to include sexual 
functioning as an outcome measure into the analysis. 
Different criteria can be used to analyze the clinical relevance of differences between patients. 
This is the first study that used Cocks’ criteria to evaluate QoL changes in prostate cancer patients. Cocks’ 
criteria are based on expert opinions and metaanalysis. One advantage of these criteria is that a distinction 
is made between longitudinal differences [14] and cross-sectional differences [15]. Another advantage of 
Cocks’ criteria is that for each QoL scale a unique division into categories is made. This is in contrast with 
criteria as proposed by Osoba [34], who made the same division into categories for all QoL scales: no 
difference (<5 points), little difference (5–10 points), moderate difference (10–20 points) and large 
difference (>20 points). Although the definition of clinical relevance according to Cocks is different from 
that of Osoba, our results suggest similar conclusions from either set of definitions. 
As both longitudinal and population differences were of small clinical importance, we conclude 
that curative radiotherapy offers the opportunity to treat prostate cancer in an effective manner, without 
substantially affecting QoL. 
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To determine the impact of late radiation-induced toxicity on health-related quality of life (HRQoL) among 
patients with prostate cancer. 
Patients and methods 
The study sample was composed of 227 patients, treated with external beam radiotherapy. Common 
Terminology Criteria for Adverse Events version 3.0 were used to grade late genitourinary and 
gastrointestinal toxicity. The European Organization for Research and Treatment of Cancer Quality of life 
Questionnaire C30 (EORTC QLQ-C30) was used to assess HRQoL at baseline, and 6, 12 and 24 months after 




Urinary incontinence and rectal discomfort significantly affected HRQoL. The impact of urinary 
incontinence on HRQoL was most pronounced 6 months after radiotherapy and gradually decreased over 
time. The impact of rectal discomfort on HRQoL was predominant at 6 months after radiotherapy, 
decreased at 12 months and increased again 2 years after radiotherapy. No significant impact on HRQoL 
was observed for any of the other toxicity endpoints, or non-toxicity related factors such as hormonal 
therapy, radiotherapy technique or age. 
Conclusion  
Urinary incontinence and rectal discomfort have a significant impact on HRQoL. Prevention of these side 





Treatment of patients with localized or locally advanced prostate cancer may involve surgery, 
radiotherapy and adjuvant hormonal therapy.  Although these treatment options result in high rates of 
tumor control, a substantial number of patients experience treatment related side effects.  Side effects 
induced by prostate cancer treatment are typically expressed in the gastrointestinal (GI) and genitourinary 
(GU) tract (Table 1).  Radiation oncologists currently focus on the prevention of these side effects by 
making adjustments in the treatment, based on the relationship between the dose to specific anatomical 
regions and the risk of a given side effect. The majority of studies that attempt to clarify this relationship 
included severe rectal bleeding as one of the primary endpoints in their analysis [1–4]. Although severe 
rectal bleeding is considered clinically relevant, the impact of mild or moderate side effects on patients’ 
daily life is less evident.  
As a result of radiation-induced side effects, patients might experience discomfort to such an 
extent that their health-related quality of life (HRQoL) is depressed [5]. Several studies showed that HRQoL 
in patients treated with definitive radiotherapy varies widely among individual patients [6–8]. This 
variation in HRQoL may be at least partly explained by differences in the occurrence and severity of the 
experienced side effects; severe toxicity is probable to result in lower levels of HRQoL. Lilleby et al. tested 
this hypothesis [9] but did not find any relationship between toxicity endpoints and HRQoL in their 
multivariate analysis. Two other studies [10,11] found a general impact of bowel, sexual and urinary 
symptoms on HRQoL. However, the impact of more  specific endpoints, such as pain after treatment, is 
still unclear. Also the question arises to whether the possible impact of side effects varies over time.  
To gain insight into the wellbeing of patients after prostate radiotherapy it is essential to know 
which and to what extent toxicity endpoints affect patients’ HRQoL, in order to make decisions that may 
prevent a decline in HRQoL after definitive radiotherapy for prostate cancer.  Therefore, the main objective 
of this study was to investigate the impact of radiation-induced toxicity on HRQoL. 
 
 
Patients and methods 
 
Patients and eligibility criteria 
The study sample was composed of 227 prostate cancer patients treated with definitive 
radiotherapy.  Patients had been included in two multicenter prospective randomized studies, 99 
patients were  included in the EORTC 22961 trial and 128 patients were included in the EORTC 22991 
trial [12,13].  
The EORTC 22961 trial started in 1997 and was designed to evaluate the influence of adjuvant 
hormonal treatment with an LHRH (luteinizing-hormone-releasing hormone) analog in patients with 
locally advanced prostate cancer treated with 3D-CRT. The EORTC 22961 protocol included patients with 
non-metastatic T1c-T2bN1-2/pN1-2 (after pelvic lymphadenectomy) or T2c-T4N0-2 (UICC 1992 TNM 
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classification) histologically confirmed adenocarcinoma of the prostate. Patients in the long arm 
(three years) received combined androgen blockade for a period of three years, while patients in the 
short arm received combined androgen blockade fora period of only six months.  
In the EORTC 22991 trial, radiotherapy alone, either 3D-CRT or IMRT, was compared with the 
same radiotherapy combined with adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic 
carcinoma. Patients in the adjuvant hormonal arm started hormonal treatment one week before 
radiotherapy with antiandrogens each day for a period of one month and additionally two injections of 
LHRH during the next six months.  
These trials were carried out according to local ethical legislations and informed consent was 
obtained from all patients. For the purpose of the current analysis, only patients that were biochemically 
failure free at the time of HRQoL assessment were included. 
 
Radiotherapy 
A planning CT of all patients was obtained in treatment position (supine). The clinical target 
volume (CTV) was defined as the prostate and the seminal vesicles. Radiotherapy was delivered with linear 
accelerators using photons with either three dimensional radiotherapy (3D-CRT) or intensity modulated 
radiotherapy (IMRT). Patients were treated 5 times a week to a total dose of 70 Gy (3D-CRT) or 78 Gy 
(IMRT). Setup accuracy was verified during delivery by matching bony anatomy and setup errors were 
corrected by using a shrinking-action-level protocol [14]. 
 
HRQoL and toxicity assessment 
HRQoL and toxicity were assessed prior to the start of radiotherapy and subsequently at 6, 12 and 
24 months after completion of radiotherapy. HRQoL was measured by means of the European 
Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 (EORTC QLQ-C30) 
[15]. The current analysis covered the HRQoL scales that were considered to be affected by GI and GU 
toxicity, including global quality of life, physical functioning, social functioning, emotional functioning, role 
functioning and the symptom scale fatigue. HRQoL-scores were linearly converted to a scale ranging from 
0–100, according to EORTC guidelines. For the functional and global health status/quality of life scales, 
higher scores represent a better level of functioning. For the symptom scales, higher scores represent a 
greater degree of symptoms.  
Patients’ toxicity was graded according to the Common Terminology Criteria for Adverse Events 
V3.0 (CTCAE 3.0) scoring system [16]. Toxicity was assessed using questionnaires, filled out by patients at 
the department of radiation oncology of the University Medical Center Groningen (UMCG). The 
questionnaires have been previously used in a multicenter randomized phase III trial [17] and at our 
institute [18]. Using these questionnaires and with additional objective physician findings, such as medical 
interventions, the different endpoints of GI and GU toxicities were scored individually, ranging from grade 
0–3 (Table 1). 
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To investigate the relationship between radiation-induced toxicity and the different domains of 
HRQoL a Multivariate Analysis of Variance (MANOVA) was used. The main advantage of the use of a 
MANOVA in this study is that the multiple dependent variables over analyzing multiple dependent 
variables using multiple ANOVA’s is that it also takes into account the inter-correlations between multiple 
dependent variables. Second, MANOVA has greater power than ANOVA [19], although the power of 
MANOVA decreases with increasing correlation [20]. Third, this multivariate approach protects against 
type I errors. Wilks’ lambda (often referred to as the U-statistic) was used to test the impact of each 
prognostic factor. Wilks’ lambda can take values ranging between 0, indicating large differences in group 
means, and 1, indicating no differences in group means.  
The relationship between radiation-induced toxicity and HRQoL was analyzed by means of a two-
step approach. In the first step, the impact of all GI and GU endpoints on different domains of HRQoL six 
months after radiotherapy was analyzed. The factors that were  significantly associated with HRQoL in the 
first step were analyzed in a multivariate model. To investigate the robustness of the multivariate model 
a backwards analysis was applied using a p-value >0.05 for removal. The statistical analysis was based on 
a similar approach as used in a study on head and neck cancer patients by Langendijk et al. [21].  
The mean scores of the HRQoL scales observed among patients with grade 1 and grade P2 
toxicities were compared to those observed among patients with grade 0 toxicity at 6 months after 
radiotherapy. The clinical relevance of the differences in the mean scores of the HRQoL scales between 
groups was classified as effect sizes using Cohen’s D, defined as small (0.20–0.49), moderate (0.50–0.79) 
and large (P>0.80) effect sizes [22,23]. To investigate whether the impact of the CTCAE late morbidity 
scales changed over time, differences at baseline were tested. Additionally, effect sizes at 12 and 24 




Sample description and compliance 
The majority of patients was treated with adjuvant hormonal therapy and 3D-CRT. The median 
age was 70 years (range 53–85). Patients’ characteristics and treatment modalities are listed in Table 2. 
Patients’ compliance on either questionnaire is listed in Table 2. Of the 224 patients who were 
biochemically failure free 6 months after radiotherapy, 188 patients filled out both questionnaires (84%). 













Age       
  ≤ 70 years 116 51 
  >70 years 111 49 
Tumor 
classification       
  T1 85 37 
  T2 68 30 
  T3 74 33 
PSA        
  < 10 50 22 
  10-20 97 43 
  20-40 60 26 
  >40 20 9 
Adjuvant 
treatment       
  RT only 71 31 
  
RT and adjuvant 
hormonal therapy 156 69 
Radiotherapy 
Modality       
  IMRT:  78 Gy 70 31 
  3D-CRT: 70 Gy 157 69 
        
Compliance 
Toxicity 
assessment       
  Baseline                     222 98 
  6 months after RT    200 89 
  
12 months after 
RT    184 84 
  
24 months after 
RT   187 88 
Compliance 
HRQoL 
assessment       
  Baseline 221 97 
  6 months after RT 209 92 
  
12 months after 
RT 207 95 
  
24 months after 
RT 203 95 
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Association between toxicity endpoints and HRQOL 
In the first analysis, a one-factor model was setup for all candidate variables at 6 months after 
radiotherapy (Table 3). The candidate prognostic factors included all GI and GU toxicity endpoints, patient 
characteristics and treatment modalities. The dependent variables in this analysis consisted of the overall 
quality of life, the four functioning scales and the symptom scale fatigue. Significant associations were 
found between HRQoL and the toxicity endpoints urinary incontinence and rectal pain/painful  cramps.  
In the multifactor model, only the significant variables from the one-factor model were entered 
into the multivariate model. To investigate the robustness of this model, a multivariate backward analysis 
was performed. In this analysis, all factors were entered into the model simultaneously and were 
backwards excluded. The multi-factor model showed, identical to the one-factor model, no effect of 
radiotherapy technique, hormonal treatment (yes vs. no) and patient characteristics. Two toxicity  
endpoints significantly affected patients’ HRQoL; urinary incontinence and rectal pain/painful cramps. No 
significant pre-treatment differences in HRQoL were found between the toxicity groups. 
 
Urinary incontinence and HRQoL outcome 
Table 4 summarizes the means of the toxicity endpoints that had a significant impact on HRQoL. 
Effect sizes were calculated comparing grade 1 vs. grade 0 and grade 2–3 vs. grade 0 using Cohen’s D. 
Urinary incontinence had an impact on all of the HRQoL scales. Comparing grade 0 with 1, small and 
moderate effect sizes were noted for the HRQoL scales. In particular, urinary incontinence had a marked 
impact on social functioning. The differences between grade 0 and grade 2–3 patients ranged from small 
to large.  Physical functioning and global quality of life were particularly affected by urinary incontinence 
(effect size >0.70). 
 
Rectal pain/painful cramping and HRQoL outcome 
Rectal pain and painful cramping had a major impact on HRQoL. In relation to patients with grade 
0, a moderate effect was observed for grade 1 regarding global quality of life. Large effect sizes were noted 
for patients with grade 2–3 as compared to patients with grade 0, especially for social functioning (Cohen’s 
D >0.85). Small to moderate effect sizes were observed for the other HRQoL scales. 
 
Changes over time: urinary incontinence  
The prevalence of occasional and spontaneous urinary incontinence remained stable over the 
three follow-up time points, i.e. 20%, 20%, 21% (grade 1) and 6%, 7% and 8% (grade 2). Effect sizes of 
urinary incontinence over time are depicted in Fig. 1a and b. Fig. 1a shows the differences in effect sizes 
over time between grade 0 and grade 1 patients. The magnitude of the effect sizes decreased over time. 
The  highest effect sizes were noted at 6 months after radiotherapy. Fig. 1b shows the differences in effect 
sizes over time between grade 0 and grade 2–3 patients. Generally speaking, the effect sizes decreased at 
12  months but increased again at 24 months after radiotherapy. 
 
Changes over time: rectal pain/painful cramping 
The total number of patients with any level of rectal discomfort (both mild and moderate) 
remained stable over time, covering 18% of patients on all three time points. However, the prevalence of 
moderate discomfort decreased over time, 6%, 2% and 2%, respectively. As time progressed more patients 
 
were observed with mild pain, 12%, 16% and 6%, respectively. Effect sizes of rectal pain/painful cramping 
over time are depicted in Fig. 1c. Because of the low incidence (only 4 cases) of grade 2 rectal discomfort, 
no effect sizes could be calculated for this group. The effect sizes comparing grade 1 with grade 0 
decreased 12 months after radiotherapy and increased again 24 months after radiotherapy. 
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The primary objective of this study was to investigate the impact of radiation-induced toxicity on 
HRQoL. To our knowledge this is the first study that shows that HRQoL is significantly affected by two 
specific treatment-related symptoms; urinary incontinence and rectal discomfort. Remarkably, a toxicity 
grading as low as grade 1 affects patients’ HRQoL.  
The results of this study are in line with research by Bacon, who showed a general impact of urinary 
and bowel complaints on quality of life [10]. We found, more specifically, that urinary incontinence and 
rectal discomfort is a cause for this depressed HRQoL. In a comparable study, Lilleby showed a univariate 
significant impact of urinary incontinence and bowel complaints on HRQoL [9]. However, this impact could 
not be confirmed in their multivariate analysis. In the current study, the functioning scales were regarded 
as intercorrelating dependent variables in a MANOVA design. In addition, we used undichotomized HRQoL 
scores, giving the opportunity to increase statistical power. The optimization of the power to show an 
effect was necessary because the prevalences of toxicity were relatively low and could therefore dilute 
HRQoL scores of patients. Despite the low prevalences, a significant and clinically relevant effect of urinary 
incontinence and rectal discomfort was observed on both a univariate and multivariate level. Low 
prevalences did affect the power to show an impact of fecal incontinence on HRQoL. Fecal incontinence 
was observed in only 7 patients, which was too low to reliably investigate the association between fecal 
incontinence and HRQoL.  
 
The impact of urinary incontinence on HRQoL and possible clinical consequences  
Urinary incontinence had a major impact on HRQoL, especially on global quality of life, physical 
functioning, emotional functioning and fatigue. However, the negative impact on HRQoL decreased over 
time. This decrease is in accordance with the findings of Sanda et al., who investigated patients’ complaints 
using the Expanded Prostate Cancer Index Composite (EPIC-26) [24]. In that study, urinary incontinence 
worsened only temporarily. Remarkably, in the present study, the prevalence of urinary incontinence 
remained stable over time, whereas the impact of urinary incontinence on HRQoL decreased. This might 
indicate that patients develop effective coping strategies or change their internal standards, values and 
conceptualization of quality of life, known in HRQoL literature as response shift [25]. 
New radiation delivery techniques, such as image-guided radiotherapy (IGRT) or proton therapy 
may contribute to a reduction of the risks on radiation-induced side effects and subsequently to higher 
levels of HRQoL after treatment. In order to prevent radiation-induced side effects, it is essential to know 
the relationship between radiation dose distribution in adjacent organs at risk and the risk on a given side 
effect using normal tissue complication probability (NTCP) models. A systematic review on dose–volume 
effect relationships showed that, in general, dose-escalation increases GU toxicity, resulting from an 
unavoidable increase of dose to the caudal part of the bladder [26]. Heemsbergen et al. [27] showed that 
dose hot-spots in the trigonum region of the bladder may contribute to urinary obstruction. However, no 
conclusive data are available in current literature on a possible relationship between the dose to specific 
parts of the urinary tract and urinary incontinence. In order to prevent a decline in HRQol after 
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The primary objective of this study was to investigate the impact of radiation-induced toxicity on 
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specific treatment-related symptoms; urinary incontinence and rectal discomfort. Remarkably, a toxicity 
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The impact of rectal discomfort on HRQoL and possible clinical consequences 
The incidence of rectal pain in the present study may seem high compared to a study by Fonteyne 
et al. [28]. However, another study by Pinkawa [29] showed higher incidences of rectal pain. The incidence 
depends strongly on the definition of rectal pain. In the present study, rectal pain covered questions on 
painful cramping, pain during defecation and painful urgency. Rectal pain may be regarded as a symptom 
of radiation proctitis, which leads to a loss of distensibility of the rectum or rectal structuring [30]. Other  
signs and symptoms of radiation proctitis include rectal bleeding, increased stool frequency and fecal 
incontinence. A number of authors reported on the relationship between the dose to the anorectal or anal 
wall and the incidence of radiation proctitis symptoms [31–34]. Also, research by Nguyen showed that 
V60anterialwall was associated with a decrease in gastro-intestinal HRQoL [35]. However, no evidence exists on 
the relationship between the dose to specific anatomical regions and rectal pain or painful cramping. From 
this point of view, it remains uncertain if the clinical introduction of new radiation techniques aiming at 
reducing the dose to specific anatomical structures will also results in a reduction of rectal pain and 
eventually in better HRQoL. To investigate the uncertainties surrounding the concept of radiation proctitis 
the new EORTC proctitis module, including items regarding pain and painful cramping [36], offers an 
opportunity to look at this toxicity more closely. 
 
The impact of other prognostic factors on HRQoL and possible clinical consequences 
In the present study, no effect of radiation technique (3D-CRT versus IMRT) and hormonal 
therapy (yes versus no) on HRQoL was observed. Similar results were found by Lips et al. [37]: IMRT 
provides a possibility to increase the radiation dose to the PTV, without deteriorating HRQoL. In the 
same study, hormonal therapy did not influence HRQoL as measured with the EORTC QLQ-C30. Although 
hormonal therapy did not have a significant influence on global quality of life, influence on sexual HRQoL 
scales are evident [38,39]. Lips et al. [40] showed a decrease in sexual activity after radiotherapy and 
literature shows an increase in erectile dysfunction after radiotherapy [41,42]. Kyrdalen [43] found that 
poor sexual drive was significantly associated with a low HRQoL, whereas erectile dysfunction and 
medication to counter erectile dysfunction were not.  
Most studies reporting on NTCP models in prostate cancer focus on rectal bleeding [1–7]. 
Although we could not find a significant association between rectal bleeding and HRQoL, this result 
should be interpreted with some caution. Most of the rectal bleeding we encountered in our data was 
classified as grade 1. Apparently, this grading does not influence HRQoL. However, it could be assumed 
that patients with more severe rectal bleeding, including temporarily blood loss or the need to undergo 
interventions such as laser coagulation or hyperbaric oxygen, do experience a worsening in HRQoL. 
Although our results show a decrease in HRQoL after radiotherapy due to side effects, only a 
relatively small number of patients actually experience these side effects, possibly diluting our results. 
Therefore, we cannot be totally conclusive about the explanation of a decrease in HRQoL after 
radiotherapy. Also, our group was relatively heterogeneous, considering different radiotherapy 
treatment modalities and considering different adjuvant hormonal therapy options. Although these 
variables did not influence HRQoL in our study, additional research with a more homogeneous patient 
group is needed to ascertain these results.  
 
The focus of the current study was on general domains of HRQoL. It may well be important to 
analyze the impact of other treatment related symptoms by means of the QLQ-PR25 [44]. However, it 
should be taken into account that radiation induced toxicity as can be derived from the QLQ-PR25 is 
singly patient-rated, whereas the CTCAE toxicity endpoints used in our study offered the opportunity to 
investigate the impact of possible clinical interventions, that are not included in the QLQ-PR25.  
In order to categorize clinically meaningful changes Cohen’s effect sizes were used in the current 
study. Another method to analyse clinically meaningful changes is Osoba’s 10 point difference [45]. The 
criteria from Osoba are based on research on patients with either breast cancer or small-cell lung cancer. 
As prostate cancer patients may experience their functioning in daily life after radiotherapy differently, 
we argue that the meaning of clinically important differences in health related quality of life may also be 
different.  Therefore we choose to use the statistical criteria as proposed by Cohen that are more 
universal and do less depend on the patient group analyzed. 
 
Conclusion 
Urinary incontinence and rectal discomfort have an invalidating impact on prostate cancer 
patients’ HRQoL after radiotherapy. Current studies on prostate cancer radiotherapy focus mainly on 
severe toxicity (grade P2), whereas even slight toxicity affects a patient’s HRQoL. The impact of severe 
rectal bleeding on a patient’s HRQoL may be obvious, but also more temporary as compared to the 
persisting impact of urinary incontinence and rectal discomfort. 
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Background and purpose 
Curative radiotherapy for prostate cancer may lead to anorectal side effects, including rectal bleeding, 
fecal incontinence, increased stool frequency and rectal pain. The main objective of this study was to 
develop multivariable NTCP models for these side effects. 
 
Material and methods 
The study sample was composed of 262 patients with localized or locally advanced prostate cancer (stage 
T1–3). Anorectal toxicity was prospectively assessed using a standardized follow-up program. Different 
anatomical subregions within and around the anorectum were delineated. A LASSO logistic regression 
analysis was used to analyze dose volume effects on toxicity. 
 
Results  
In the univariable analysis, rectal bleeding, increase in stool frequency and fecal incontinence were 
significantly associated with a large number of dosimetric parameters. The collinearity between these 
predictors was high (VIF > 5). In the multivariable model, rectal bleeding was associated with the 
anorectum (V70) and anticoagulant use, fecal incontinence was associated with the external sphincter 
(V15) and the iliococcygeal muscle (V55). Finally, increase in stool frequency was associated with the 
iliococcygeal muscle (V45) and the levator ani (V40). No significant associations were found for rectal pain. 
 
Conclusions 
Different anorectal side effects are associated with different anatomical substructures within and around 
the anorectum. The dosimetric variables associated with these side effects can be used to optimize 
radiotherapy treatment planning aiming at prevention of specific side effects and to estimate the benefit 





Dose escalation in external beam radiotherapy results in increased biochemical tumor control for 
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Table 1: Patient and treatment characteristics 
  
    
Number of 
patients % 
Age       
  ≤ 70 years 151 58 
  >70 years 111 42 
Tumor classification       
  T1 102 39 
  T2 114 44 
  T3 46 18 
PSA        
  < 4 9 3 
  4-10 82 31 
  >10 171 65 
Gleason       
  5-6 95 36 
  7 106 41 
  8-10 61 23 
Treatment related factors       
  Hormonal therapy 113 43 
  Fiducial markers 80 31 
Pre-treatment related factors       
  History of diabetes  32 12 
  Smoking (15 missing) 100 38 
  History of cardiovascular disease 86 33 
  History of abdominal surgery 92 35 
  Anticoagulants use 92 35 
        
        
Target delineation 
Two clinical target volumes (CTV) were defined, one for the prostate and one for the seminal 
vesicles. Each CTV was expanded 10 mm in three dimensions to obtain the corresponding planning target 
volumes (PTV), using the automatic expansion algorithm of the treatment-planning system. 
Organ at risk delineation 
The cranial border of the anorectum was defined at the location where the rectum turned 
horizontally into the sigmoid colon but not superior to the caudal border of the sacroiliac joint. The caudal 
border of the rectum was defined to include the anus but not lower than the inferior border of the ischial 
tuberosity. The anorectum was divided into two sections: the anal canal, corresponding to the inferior part 
(ischial tuberosity to 3 cm superior) and the rectum, corresponding to the remaining superior part (Fig. 
1a). The anal and rectal walls were defined as the outermost 3 mm of the anal canal and rectum (Fig. 1b 
and c). Subsequently, the anal and rectal structures were divided into an anterior and a posterior part. 
 
 The pelvic floor muscles were delineated as described by Smeenk et al. [10]. The internal anal 
sphincter (IAS) was defined as the distal extension of the smooth muscle layer of the anorectum (Fig. 2). 
The external anal sphincter (EAS) encircles the internal sphincter. The puborectal muscle (PRM) is a U-
shaped muscle connecting to the pubic bone. The cranial extension is defined as the Iliococcygeus muscle 
(ICM). The PRM and ICM together form the levator ani (LA) muscle. 
 
 
Figure 1   a. Sagittal view of bladder (green), prostate (yellow), anal canal (purple), rectum (red). 
                 b. Transverse view of the anal wall 














 a.  c. 
b. 
Figure 2a. External anal sphincter (EAS) : blue 
                  Internal anal sphincter (IAS): purple 
              b. Puborectal muscle (PRM) 
              c. Iliococcygeus muscle (ICM) 
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              b. Puborectal muscle (PRM) 







Side effects were assessed prospectively using questionnaires, filled out by patients at the 
department of Radiation Oncology, UMCG. The questionnaires have been previously used in a multicenter 
randomized phase III trial [11] and at our institute [12]. Using these questionnaires and additional objective 
data on medical interventions, such as the prescription of medication, the different endpoints were scored 
according to the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE 3.0) scoring system 
[13], finally resulting in a single score per endpoint for the incidence of toxicity over the follow-up interval. 
The minimal follow up of patients alive was 3 years.  
Rectal bleeding was defined as daily loss of blood, requiring one or more laser coagulation (CTCAE 
grade≥2), fecal incontinence was defined as the unwilling loss of stool (CTCAE grade≥2), stool frequency 
was defined as an increase of more than three times per day compared to baseline (CTCAE grade≥2) and 
rectal pain was defined as severe pain during defecation (CTCAE grade≥2). 
Statistical analysis 
The candidate dosimetric predictors of the four endpoints in our analysis were selected based on 
available literature on both prostate NTCP modeling [4,10] and on pathophysiology of late rectal 
dysfunction [9] and included the mean dose for each organ at risk and the relative volumes receiving 5–
70 Gy, in 5 Gy bins (V5–V70). Additionally, equivalent uniform dose (EUD) parameters with n ranging from 
0.05 to 0.5 were included into the model [14,15]. Finally, we included age, adjuvant hormonal treatment, 
and pretreatment factors (Table 1), which were retrieved retrospectively from the patient charts, as 
candidate predictors. Patients with missing data in the candidate dataset were removed from the analysis. 
To develop a prediction model for each endpoint, a univariable logistic regression analysis was 
performed first to show the crude effect of each candidate variable on every endpoint. For the 
development of the multivariable prediction models the least absolute shrinkage and selection operator 
(LASSO) method was used, which is a logistic regression analysis with a penalty for the magnitude of the 
regression coefficients to prevent overfitting. The optimal penalty value was determined using cross-
validation. Because of the high collinearity of the candidate predictors, the set of variables was further 
reduced prior to the LASSO analysis, until the variance inflation factor (VIF) was smaller than 5. First, (if VIF 
> 5) all variables with univariable associations with p > 0.157 (Wald test) were removed. Subsequently, (if 
still VIF > 5) the set of dosimetric variables was reduced, such that for each structure (or set of overlapping 
structures) only the strongest predictor remained (as measured by the likelihood of the corresponding 
univariable model). Finally, if multivariable analysis resulted in a negative coefficient for a dosimetric 
variable, that variable was removed from the analysis.  
Model performance was described using various validation measures [16,17]. The discriminating 
ability of the model was described by the Area Under the receiver operating characteristic curve (AUC). 
The discrimination slope was calculated as the absolute difference between the mean predicted NTCP 
value for patients with and without the outcome. Nagelkerke’s R2 was calculated as a pseudo measure of 
explained variance. Finally, the gain and intercept of the model calibration were calculated, and the 
calibration was evaluated using a Hosmer–Lemeshow test with 10 equal groups [18]. The model 
performance was internally validated and corrected for optimism with regular bootstrapping [19]. Results 





Twelve out of 256 patients (4.7%) experienced grade 2 or higher rectal bleeding. The candidate 
predictors of severe rectal bleeding included dosimetric predictors of all anorectal (sub)structures and pre-
treatment variables diabetes, age, cardiovascular disease, abdominal surgery, anticoagulants use and 
adjuvant hormonal treatment.  In the univariable analysis the V50-V70, different EUD’s and mean dose for 
anorectum, rectum, rectal wall, rectum-posterior and rectum-anterior were associated with rectal 
bleeding (Table 2). In addition, a borderline significant relationship was found with cardiovascular disease 
and anticoagulants use. No association was observed between rectal bleeding and the other pre-
treatment related factors (Table 1). Because of high collinearity among the predictors (VIF >5), the set of 
candidate variables was reduced prior to the multivariable LASSO analysis. Also, because all patients that 
used anticoagulants had a history of cardiovascular disease, the latter variable was dropped. In the final 
model, the volume of the anorectum receiving ≥70 Gy (anorectum(V70)) and the use of anticoagulants 
predicted rectal bleeding with a corrected AUC of 0.88 (CI: 0.78-0.97; see all measures in table 3). In 
individual cases, the risk of rectal bleeding can be estimated using the following equation: 
NTCP =	 #(#%	&'() 
Where S is defined as: 
* = −8.09 + 0.32 ∙ (anorectum	(V70)	) + 1.19 ∙ (anticoagulant	use)	 
with anorectum(V70) in relative volume % and anticoagulant use is 1 (yes) or 0 (no). 
 The Hosmer-Lemeshow test was not significant (chi square 9.85; df 8; p=0.28), indicating good agreement 
between expected and observed complication rates (Figure 3a).  
In total, 20 out of 256 patients experienced fecal incontinence (7.8%). The candidate predictors of 
fecal incontinence included dosimetric predictors of all anorectal (sub)structures and all pelvic floor 
muscles. In the univariable analysis low, intermediate and high dose and different EUD’s of the internal 
anal sphincter, external anal sphincter, iliococcygeal muscle and levator ani muscle were associated with 
fecal incontinence (Table 2). The variance inflation factor showed high collinearity (VIF > 5) among the 
predictors, and the number of dosimetric variables was therefore reduced prior to multivariable analysis. 
The internal sphincter was excluded because this variable resulted in a model with a negative dosimetric 
coefficient. The LASSO analysis resulted in a model with two predictors, including the volume of the 
external sphincter receiving ≥ 15 Gy and the volume of the iliococcygeal muscle receiving ≥ 55 Gy, with a 
corrected AUC of 0.85 (CI: 0.76- 0.94; see all measures in table 3). In individual cases, the risk of fecal 
incontinence can be estimated using the following equation: 
NTCP =	 #(#%	&'() 
Where S is defined as: 
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Table 2: Univariable logistic regression analysis for rectal bleeding, stool frequency and fecal 
incontinence 
      Odds ratio*,** p-Value** 
Rectal bleeding ≥ grade 2 (n=12)       
  Cardiovascular disease   2.87 0.079 
  Anticoagulants use   3.00 0.065 
  Anorectum mean dose 1.11 0.105 
    V50-V70 1.05-1.58 <0.001 - 0.068 
    EUD (0.05-0.50) 1.29-2.91 <0.001 - 0.008 
  Rectalwall V50-V70 1.05-1.20 <0.001 - 0.042 
    EUD (0.05-0.50) 1.17-2.41 <0.001 - 0.033 
  Rectum V50-V70 1.04-1.38 <0.001 - 0.051 
    EUD(0.05-0.50) 1.24-2.65 <0.001 - 0.013 
  Rectum-posterior V50-V70 1.04-1.71 <0.001 - 0.020 
    EUD(0.05-0.50) 1.19-1.40 <0.001 - 0.001 
  Rectum-anterior V55-V75 1.05-1.15 <0.001 - 0.046 
    EUD(0.05-0.50) 1.20-2.63 <0.001 - 0.028 
          
Fecal incontinence (n=20)       
  Internal anal sphincter (IAS) mean dose 1.09 0.023 
    V10-V45 1.04-1.05 0.007-0.150 
  External anal sphincter (EAS) mean dose 1.19 <0.001 
    V10-V70 1.07-1.08 <0.001-0.108 
    EUD(0.20-0.50) 1.15-1.19 <0.001-0.009 
  Iliococcygeal muscle (ICM) mean dose 1.09 0.014 
    V40-V70 1.03-1.04 0.001-0.110 
    EUD(0.10-0.20) 1.08-1.10 0.028-0.029 
  Levator ani muscle (LAM)*** mean 1.09 0.13 
    V40-V65 1.04-1.05 0.018-0.076 
          
Increased stoolfrequency >3  (n=29)       
  Iliococcygeal muscle (ICM) mean dose 1.13 <0.001 
    V25-V65 1.04-1.72 <0.001-0.120 
    EUD(0.5-2) 1.15-1.16 <0.001 
  Puborectal muscle (PRM) mean dose 1.07 0.077 
    V25-V55 1.03-1.65 0.002-0.076 
  Levator ani muscle (LAM)*** mean dose 1.2 <0.001 
    V25-V70 1.03-1.24 <0.001-0.070 
    EUD(0.5-2) 1.20-1.26 <0.001-0.002 
          
* For dose variables OR: increase per 1 Gy increase in dose     
  For volume parameters: increase per 1% increase in volume   
**     range is displayed when > 1 variable, only results with p<0.157 are shown   
***   Levator ani muscle=Iliococcygeal muscle + Puborectal muscle   
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! = −7.00 + 0.064 ∙ (external	sphincter(V15)) + 0.015 ∙ (iliococcygeal	muscle(V55))	 
With external sphincter(V15) and iliococcygeal muscle(V55) in relative volume %. 
The Hosmer-Lemeshow test had a chi square of 7.27 (df=8, p=0.51), indicating good agreement between 
expected and observed complication rates (Figure 3b). 
A total number of 29 out of 254 patients (11.4%) experienced an increase in stool frequency of 
more than 3 compared to baseline. The candidate predictors of an increase in stool frequency included 
dosimetric predictors of all anorectal (sub)structures and all pelvic floor muscles. In the univariable analysis 
the mean and intermediate dose to the iliococcygeal muscle, puborectal muscle and levator ani muscle 
and different EUD’s were associated with increased stool frequency (Table 2). The variance inflation factor 
showed high collinearity (VIF > 5) among the predictors. Based on the LASSO variable selection method, 
the final multivariable analysis with the best model performance resulted in a model with two predictors, 
including the volume of the iliococcygeal muscle receiving ≥ 45 Gy and the volume of the levator ani 
receiving ≥ 40 Gy, with a corrected AUC of 0.79 (CI 0.72-0.86). In individual cases, the risk of increased 




Where S is defined as: 
! = −7.78 + 0.027 ∙ (iliococcygeal	muscle(V45) + 0.046	 ∙ (levator	ani	muscle(V40)	 
With iliococcygeal muscle(V45) and levator ani muscle(V40) in relative volume %.  
The Hosmer-Lemeshow test was not significant (chi square 7.43; df 8; p=0.49), indicating good agreement 
between expected and observed complication rates (Figure 3c). 
In total, 16 patients (6.1%) experienced rectal pain (≥grade 2). The candidate predictors of rectal 
pain included dosimetric predictors of all anorectal (sub)structures and all pelvic floor muscles.  In the 
univariable and multivariable analysis no significant associations were found for any of the dosimetric or 
pre-treatment predictors with rectal pain.    
Discussion 
 
The main objective of this study was to develop multivariable NTCP models for rectal bleeding, 
incontinence, stool frequency and rectal pain based on pretreatment and dosimetric variables of different 
anatomical subregions within or around the anorectum. For three endpoints the multivariable analysis 
resulted in models with two highly predictive variables. Rectal bleeding was best predicted by the V70 of 
the anorectum and the use of anticoagulants. Incontinence was best predicted by the V15 to the external 
anal sphincter and the V55 of the iliococcygeal muscle. Stool frequency was best predicted by the V45 of 
the iliococcygeal muscle and the V40 of the levator ani muscle. No significant associations were found for 
rectal pain.  
Normal tissue complication probability (NTCP) models for late rectal bleeding,














































































































































































































































































































































































































































































































































































































































































   
   






































































































































































! = −7.00 + 0.064 ∙ (external	sphincter(V15)) + 0.015 ∙ (iliococcygeal	muscle(V55))	 
With external sphincter(V15) and iliococcygeal muscle(V55) in relative volume %. 
The Hosmer-Lemeshow test had a chi square of 7.27 (df=8, p=0.51), indicating good agreement between 
expected and observed complication rates (Figure 3b). 
A total number of 29 out of 254 patients (11.4%) experienced an increase in stool frequency of 
more than 3 compared to baseline. The candidate predictors of an increase in stool frequency included 
dosimetric predictors of all anorectal (sub)structures and all pelvic floor muscles. In the univariable analysis 
the mean and intermediate dose to the iliococcygeal muscle, puborectal muscle and levator ani muscle 
and different EUD’s were associated with increased stool frequency (Table 2). The variance inflation factor 
showed high collinearity (VIF > 5) among the predictors. Based on the LASSO variable selection method, 
the final multivariable analysis with the best model performance resulted in a model with two predictors, 
including the volume of the iliococcygeal muscle receiving ≥ 45 Gy and the volume of the levator ani 
receiving ≥ 40 Gy, with a corrected AUC of 0.79 (CI 0.72-0.86). In individual cases, the risk of increased 




Where S is defined as: 
! = −7.78 + 0.027 ∙ (iliococcygeal	muscle(V45) + 0.046	 ∙ (levator	ani	muscle(V40)	 
With iliococcygeal muscle(V45) and levator ani muscle(V40) in relative volume %.  
The Hosmer-Lemeshow test was not significant (chi square 7.43; df 8; p=0.49), indicating good agreement 
between expected and observed complication rates (Figure 3c). 
In total, 16 patients (6.1%) experienced rectal pain (≥grade 2). The candidate predictors of rectal 
pain included dosimetric predictors of all anorectal (sub)structures and all pelvic floor muscles.  In the 
univariable and multivariable analysis no significant associations were found for any of the dosimetric or 
pre-treatment predictors with rectal pain.    
Discussion 
 
The main objective of this study was to develop multivariable NTCP models for rectal bleeding, 
incontinence, stool frequency and rectal pain based on pretreatment and dosimetric variables of different 
anatomical subregions within or around the anorectum. For three endpoints the multivariable analysis 
resulted in models with two highly predictive variables. Rectal bleeding was best predicted by the V70 of 
the anorectum and the use of anticoagulants. Incontinence was best predicted by the V15 to the external 
anal sphincter and the V55 of the iliococcygeal muscle. Stool frequency was best predicted by the V45 of 
the iliococcygeal muscle and the V40 of the levator ani muscle. No significant associations were found for 




The association between the dose to the anorectum as a solid single organ and the complication 
probability has been extensively investigated in other studies [8,20,21]. Although our study included a 
large number of anatomical substructures within the anorectum to predict rectal bleeding, the results 
suggest identical constraints to the V70 of the anorectum as mentioned in a review on dose-volume effects 
in normal tissue [4]. In the current study the addition of dose to different anatomical substructures within 
the anorectum did not result in a better model for the prediction of rectal bleeding. Notably, the planned 
doses in the specific substructures of the anal and rectal walls were not better predictors for rectal 
bleeding than the dose in the larger encompassing anorectum. A possible explanation is that the actual 
given dose is blurred compared to the planned dose due to setup-errors and motion, and that planned 
dose in larger encompassing structures is more representative for the actual given dose than planned dose 
in small wall-like substructures. The actual given dose may be more in line with the planned dose by use 
of an endorectal balloon [10]. However, patients in our cohort were not treated with an endorectal balloon 
and therefore future research should focus on patients treated with endorectal balloons in order to further 
specify the anatomical substructures that are responsible for rectal bleeding.  
Fransson et al. [22] observed a large difference in incontinence and stool frequency between 
prostate cancer patients treated with EBRT and age-matched controls. Smeenk et al. were the first to try 
to find an explanation for these incontinence related complaints by analyzing the relationships with the 
dose to different pelvic floor muscles by means of a univariable analysis [10]. The results of the univariable 
analysis of the current study are in line with those results, i.e., that the doses to all of the pelvic floor 
muscles were highly associated with incontinence. In contrast, the multivariable analysis revealed that 
only the dose to the iliococcygeal muscle (part of the levator ani muscle) and external sphincter were 
independently associated with fecal incontinence. The question may arise why specifically these structures 
are involved in these incontinence related complaints. The external sphincter is responsible for the 
voluntary movement of stool through the anus, in contrast to the internal sphincter, which is involuntary 
[9], and is cranially attached to the levator ani muscle. The current study shows that both the lower part 
(external sphincter) and upper part (iliococcygeal muscle) of the pelvic floor muscles are involved in 
incontinence. This is in line with [23] and results described by Dobben et al. [24], where incontinence was 
related to external sphincter defects, such as anal sphincter atrophy. More specifically, Yeoh [25] found 
that weakening of the external sphincter (and not the internal) was observed among incontinent patients 
and manometry testing showed progressive reduction of anal pressure among EBRT (external beam 
radiotherapy) treated patients due to weakening of the external sphincter. In the current study, increase 
in stool frequency was highly associated with the dose to different pelvic floor muscles, i.e., the levator 
ani muscle and, in particular, the iliococcygeal muscle. This is in agreement with a study on frequent 
voiding [26], in which worsening of levator ani defects was related to frequent voiding. Another study [27] 
showed that clinical improvement after rectal defects was associated with a strengthening of the levator 
ani muscle by pelvic floor exercises. These exercises may offer an additional opportunity to decrease the 
perseverance of rectal defects that may be caused by radiation therapy.  
The iliococcygeal muscle is part of the levator ani and as a result, the correlation between these 
predictors was relatively high (0.79). However, both remained predictive in the multivariable model, 
indicating that the levator ani as a whole and particularly the iliococcygeal muscle play an essential role in 
continence and voiding.  
 
Although we tried to find an explanation for rectal pain among patients treated with EBRT for 
prostate cancer, we were not able to find any (dosimetric) predictor for this toxicity. Several researchers 
have investigated this toxicity [28,29], but to our knowledge no direct relationship between dosimetric 
parameters and pain can be found in literature. Pain is a relatively subjective endpoint, in contrast to the 
other endpoints, and other individual factors such as self-efficacy, may play a role in the pain experience 
[30]. As pain has a direct impact on the quality of life [2], further research should focus on finding other 
possible predictors of rectal pain among prostate cancer patients.  
The number of patients with severe (grade≥2) side effects in prostate cancer patients in our cohort 
is relatively small, possibly affecting the robustness of the model. The question may arise as to whether 
the internal validity of the models stated in this article is compromised by this low incidence. In order to 
address this, additional multivariable analyses with alternative methods were performed, including logistic 
regression with forward variable selection using the Wald test or bootstrapping [31] and reducing the 
variable collinearity with PCA (principal component analysis) preprocessing. These analyses all resulted in 
very similar models, with the same dominating factors, suggesting a relatively high stability of the 
associations in this dataset, independent of the method of analysis. An additional simulation analysis on 
these data [32] showed that, despite high collinearity and low incidence, the data driven selection used, 
performed relatively stable. Although highly stable in these data, we recommend to evaluate these models 
in external datasets.  
The final models presented cover different dose predictors, i.e. cutoff values derived from a Dose 
Volume Histogram (DVH). A well-known limitation of using DVH cutoff values in modeling is that only one 
point of the DVH is considered and the rest is ignored. Use of the Equivalent Uniform Dose (EUD) may be 
a solution for this problem [14,15], taking into account the whole DVH. Therefore analyses using the EUD 
as a predictor were performed. Although the EUD models performed well in the univariable analysis, for 
all endpoints the previously stated models performed better in terms of likelihood and were therefore 
presented as the final models. Although in our data single cut-off values from the DVH had better model 
performance than EUD based models, confirmation in external datasets is warranted.  
The results of this study provide important information on which anatomical structures in prostate 
cancer IMRT could be considered as organ at risk. Whether dose in these structures can be reduced using 
alternative plan optimization or dose delivery techniques, and whether this reduction will actually result 
in less side effects should be confirmed in plan comparison and prospective cohort studies.  
Different anatomical subregions are associated with different anorectal side effects. Rectal 
bleeding is associated with high doses to the anorectum and anticoagulants use, anal incontinence is 
associated with low doses to external anal sphincter and iliococcygeal muscles and increase in stool 
frequency is associated with intermediate dose to the levator ani muscles. Although internal validation 
showed good results, further evaluation in independent datasets is warranted. 
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The association between the dose to the anorectum as a solid single organ and the complication 
probability has been extensively investigated in other studies [8,20,21]. Although our study included a 
large number of anatomical substructures within the anorectum to predict rectal bleeding, the results 
suggest identical constraints to the V70 of the anorectum as mentioned in a review on dose-volume effects 
in normal tissue [4]. In the current study the addition of dose to different anatomical substructures within 
the anorectum did not result in a better model for the prediction of rectal bleeding. Notably, the planned 
doses in the specific substructures of the anal and rectal walls were not better predictors for rectal 
bleeding than the dose in the larger encompassing anorectum. A possible explanation is that the actual 
given dose is blurred compared to the planned dose due to setup-errors and motion, and that planned 
dose in larger encompassing structures is more representative for the actual given dose than planned dose 
in small wall-like substructures. The actual given dose may be more in line with the planned dose by use 
of an endorectal balloon [10]. However, patients in our cohort were not treated with an endorectal balloon 
and therefore future research should focus on patients treated with endorectal balloons in order to further 
specify the anatomical substructures that are responsible for rectal bleeding.  
Fransson et al. [22] observed a large difference in incontinence and stool frequency between 
prostate cancer patients treated with EBRT and age-matched controls. Smeenk et al. were the first to try 
to find an explanation for these incontinence related complaints by analyzing the relationships with the 
dose to different pelvic floor muscles by means of a univariable analysis [10]. The results of the univariable 
analysis of the current study are in line with those results, i.e., that the doses to all of the pelvic floor 
muscles were highly associated with incontinence. In contrast, the multivariable analysis revealed that 
only the dose to the iliococcygeal muscle (part of the levator ani muscle) and external sphincter were 
independently associated with fecal incontinence. The question may arise why specifically these structures 
are involved in these incontinence related complaints. The external sphincter is responsible for the 
voluntary movement of stool through the anus, in contrast to the internal sphincter, which is involuntary 
[9], and is cranially attached to the levator ani muscle. The current study shows that both the lower part 
(external sphincter) and upper part (iliococcygeal muscle) of the pelvic floor muscles are involved in 
incontinence. This is in line with [23] and results described by Dobben et al. [24], where incontinence was 
related to external sphincter defects, such as anal sphincter atrophy. More specifically, Yeoh [25] found 
that weakening of the external sphincter (and not the internal) was observed among incontinent patients 
and manometry testing showed progressive reduction of anal pressure among EBRT (external beam 
radiotherapy) treated patients due to weakening of the external sphincter. In the current study, increase 
in stool frequency was highly associated with the dose to different pelvic floor muscles, i.e., the levator 
ani muscle and, in particular, the iliococcygeal muscle. This is in agreement with a study on frequent 
voiding [26], in which worsening of levator ani defects was related to frequent voiding. Another study [27] 
showed that clinical improvement after rectal defects was associated with a strengthening of the levator 
ani muscle by pelvic floor exercises. These exercises may offer an additional opportunity to decrease the 
perseverance of rectal defects that may be caused by radiation therapy.  
The iliococcygeal muscle is part of the levator ani and as a result, the correlation between these 
predictors was relatively high (0.79). However, both remained predictive in the multivariable model, 
indicating that the levator ani as a whole and particularly the iliococcygeal muscle play an essential role in 
continence and voiding.  
 
Although we tried to find an explanation for rectal pain among patients treated with EBRT for 
prostate cancer, we were not able to find any (dosimetric) predictor for this toxicity. Several researchers 
have investigated this toxicity [28,29], but to our knowledge no direct relationship between dosimetric 
parameters and pain can be found in literature. Pain is a relatively subjective endpoint, in contrast to the 
other endpoints, and other individual factors such as self-efficacy, may play a role in the pain experience 
[30]. As pain has a direct impact on the quality of life [2], further research should focus on finding other 
possible predictors of rectal pain among prostate cancer patients.  
The number of patients with severe (grade≥2) side effects in prostate cancer patients in our cohort 
is relatively small, possibly affecting the robustness of the model. The question may arise as to whether 
the internal validity of the models stated in this article is compromised by this low incidence. In order to 
address this, additional multivariable analyses with alternative methods were performed, including logistic 
regression with forward variable selection using the Wald test or bootstrapping [31] and reducing the 
variable collinearity with PCA (principal component analysis) preprocessing. These analyses all resulted in 
very similar models, with the same dominating factors, suggesting a relatively high stability of the 
associations in this dataset, independent of the method of analysis. An additional simulation analysis on 
these data [32] showed that, despite high collinearity and low incidence, the data driven selection used, 
performed relatively stable. Although highly stable in these data, we recommend to evaluate these models 
in external datasets.  
The final models presented cover different dose predictors, i.e. cutoff values derived from a Dose 
Volume Histogram (DVH). A well-known limitation of using DVH cutoff values in modeling is that only one 
point of the DVH is considered and the rest is ignored. Use of the Equivalent Uniform Dose (EUD) may be 
a solution for this problem [14,15], taking into account the whole DVH. Therefore analyses using the EUD 
as a predictor were performed. Although the EUD models performed well in the univariable analysis, for 
all endpoints the previously stated models performed better in terms of likelihood and were therefore 
presented as the final models. Although in our data single cut-off values from the DVH had better model 
performance than EUD based models, confirmation in external datasets is warranted.  
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cancer IMRT could be considered as organ at risk. Whether dose in these structures can be reduced using 
alternative plan optimization or dose delivery techniques, and whether this reduction will actually result 
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Background and purpose: 
Incontinence, hematuria, voiding frequency and pain during voiding are possible side effects of 
radiotherapy among patients treated for prostate cancer. The objective of this study was to develop 
multivariable NTCP models for these side effects. 
 
Material and Methods: 
This prospective cohort study was composed of 243 patients with localized or locally advanced prostate 
cancer (stage T1-3). Genito-urinary (GU) toxicity was assessed using a standardized follow-up program.  
The GU toxicity endpoints were scored using the Common Terminology Criteria for Adverse Events version 
3.0 (CTCAE 3.0) scoring system.  The full bladder and different anatomical subregions within the bladder 
were delineated. A least absolute shrinkage and selection operator (LASSO) logistic regression analysis was 
used to analyze dose volume effects on the four individual endpoints. 
 
Results: 
In the univariable analysis, urinary incontinence was significantly associated with dose distributions in the 
trigone (V55-V75, mean). Hematuria was significantly associated with the bladder wall dose (V40-V75, 
mean), bladder dose (V70-V75), cardiovascular disease and anticoagulants use. Pain during urinating was 
associated with the dose to the trigone (V50-V75, mean) and with trans transurethral resection of the 
prostate (TURP). In the final multivariable model urinary incontinence was associated with the mean dose 
of the trigone. Hematuria was associated with bladder wall dose (V75) and cardiovascular disease, while 
pain during urinating was associated with trigone dose (V75) and TURP. No significant associations were 
found for increase in voiding frequency. 
 
Conclusions: 
Radiation-induced urinary side effects are associated with dose distributions to different organs as risk. 
Given the dose effect relationships found, decreasing the dose to the trigone and bladder wall may reduce 





The introduction of intensity modulated radiotherapy (IMRT) and dose escalation has resulted in increased 
biochemical relapse free survival for localized prostate cancer (1). Despite this increase in tumor control, 
adjacent organs at risk (OAR) are exposed to high doses that may lead to increased rates of radiation-
induced side effects that have an impact on quality of life (2).  
To achieve a reduction in side effect rates by adjusting radiotherapy planning, knowledge of the 
association between complication risk and dose distribution parameters is required. 
Traditionally, a distinction is made between gastrointestinal (GI) and genitourinary (GU) side effects. Dose 
to specific substructures within and around the anorectum are associated with specific gastrointestinal 
side effects (3). Previous studies on genitourinary side effects showed the dose to the bladder was 
associated with urinary toxicity among patients treated with external beam radiotherapy (4) (5). 
Interestingly, dose to the trigone was associated with genitourinary side effects among patients treated 
with brachytherapy (6,7).  
In the vast majority of studies on GU side effects after radiotherapy, toxicity is typically scored as a single 
cumulative endpoint for all GU side effects taken together, rather than a single score for incontinence, 
hematuria, pain and increased voiding frequency individually. Presently no multivariable models exists on 
dose to regions within the bladder and specific late side effects among IMRT treated prostate cancer 
patients. Therefore, the main objective of this study was to develop multivariable NTCP (Normal Tissue 
Complication Probability) models for urinary incontinence, hematuria, pain and increased voiding 
frequency taking into account dose distributions to the bladder as a whole, several regions within the 
bladder and other candidate prognostic factors. 
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Materials and methods 
 
Patients 
This prospective cohort study was previously described in (3) and was composed of 243 patients with 
prostate cancer confined to the prostatic capsule (stage T1-3). All patients were treated with radiotherapy 
between 2005 and 2009. The minimal follow up of patients alive was 3 years. Radiotherapy was delivered 
using linear accelerators with 6 MV photons by intensity modulated radiotherapy (IMRT). Patients were 
treated 5 times a week to a total dose of 78 Gy on the planning target volume (PTV), using 2 Gy per fraction. 
In the current patient cohort, no pelvic lymph nodes were irradiated as part of the treatment. Setup 
accuracy was verified during delivery by matching bony anatomy or implanted fiducial markers. Most 
patients with locally advanced prostate cancer received adjuvant hormonal treatment (Table 1). Diabetes 
was defined as “use of hypoglycemic drugs”, smoking was defined as “any kind of smoking history”. These 
patient characteristics were retrospectively assessed from detailed patient charts. For the purpose of the 




All patients were subjected to a prospective data registration program in which complications and 
treatment results in terms of local control and survival are prospectively assessed. This is done within the 
framework of routine clinical practice in which outcome and complications are systemically scored as part 
of a quality assurance program. All data obtained and used for this study has been anonymized. 
The (Dutch) Medical Research Involving Human Subjects Act is not applicable to data collection as part of 
routine clinical practice and use of these data for scientific papers regarding the quality assurance 
program. Only research that is within the scope of the Medical Research Involving Human Subjects Act 
needs approval from an (accredited) ethics committee. Therefore, the hospital ethics committee (the 
Medisch Ethische Toetsingscommissie; METc) concluded that data collection by this program is regarded 
as part of routine patient care and granted us a waiver from needing ethical approval for the conduct of 
this study. 
 
In the Netherlands a patient of course has to give his/her consent for the collection of the extra data on 
behalf of the quality assurance program and the use of these data for scientific papers regarding the quality 
assurance program. However, according to Dutch legislation, consent is free of form, and verbal consent 
is sufficient. Therefore, patients were asked to participate in this quality assurance program and asked for 
permission to use their data for the program and scientific papers regarding the program. Refusal of 
participation was recorded in their medical record. 
Table 1: Patient and treatment characteristics 
   Number of 
patients 
% 
Age     
 ≤ 70 years  139 57 
 >70 years  104 43 
Tumor 
classification 
    
 T1  92 38 
 T2  107 44 
 T3  44 18 
PSA     
 <4  8 4 
 4-10  75 30 
 >10  160 66 
Gleason     
 5-6  87 36 
 7  97 40 
 8-10  59 24 
Treatment 
related factors 












    




 Smoking  77 32 















Development of a prediction model for late urinary incontinence, hematuria, 
pain and voiding frequency among irradiated prostate cancer patients
69
 
Materials and methods 
 
Patients 
This prospective cohort study was previously described in (3) and was composed of 243 patients with 
prostate cancer confined to the prostatic capsule (stage T1-3). All patients were treated with radiotherapy 
between 2005 and 2009. The minimal follow up of patients alive was 3 years. Radiotherapy was delivered 
using linear accelerators with 6 MV photons by intensity modulated radiotherapy (IMRT). Patients were 
treated 5 times a week to a total dose of 78 Gy on the planning target volume (PTV), using 2 Gy per fraction. 
In the current patient cohort, no pelvic lymph nodes were irradiated as part of the treatment. Setup 
accuracy was verified during delivery by matching bony anatomy or implanted fiducial markers. Most 
patients with locally advanced prostate cancer received adjuvant hormonal treatment (Table 1). Diabetes 
was defined as “use of hypoglycemic drugs”, smoking was defined as “any kind of smoking history”. These 
patient characteristics were retrospectively assessed from detailed patient charts. For the purpose of the 




All patients were subjected to a prospective data registration program in which complications and 
treatment results in terms of local control and survival are prospectively assessed. This is done within the 
framework of routine clinical practice in which outcome and complications are systemically scored as part 
of a quality assurance program. All data obtained and used for this study has been anonymized. 
The (Dutch) Medical Research Involving Human Subjects Act is not applicable to data collection as part of 
routine clinical practice and use of these data for scientific papers regarding the quality assurance 
program. Only research that is within the scope of the Medical Research Involving Human Subjects Act 
needs approval from an (accredited) ethics committee. Therefore, the hospital ethics committee (the 
Medisch Ethische Toetsingscommissie; METc) concluded that data collection by this program is regarded 
as part of routine patient care and granted us a waiver from needing ethical approval for the conduct of 
this study. 
 
In the Netherlands a patient of course has to give his/her consent for the collection of the extra data on 
behalf of the quality assurance program and the use of these data for scientific papers regarding the quality 
assurance program. However, according to Dutch legislation, consent is free of form, and verbal consent 
is sufficient. Therefore, patients were asked to participate in this quality assurance program and asked for 
permission to use their data for the program and scientific papers regarding the program. Refusal of 
participation was recorded in their medical record. 
Table 1: Patient and treatment characteristics 
   Number of 
patients 
% 
Age     
 ≤ 70 years  139 57 
 >70 years  104 43 
Tumor 
classification 
    
 T1  92 38 
 T2  107 44 
 T3  44 18 
PSA     
 <4  8 4 
 4-10  75 30 
 >10  160 66 
Gleason     
 5-6  87 36 
 7  97 40 
 8-10  59 24 
Treatment 
related factors 












    




 Smoking  77 32 


















 TURP  52 21 
PSA: Prostate-specific antigen 
TURP:transurethral resection of the prostate 
 
 
Target and organ at risk delineation 
Three Planning Target Volumes (PTV) were defined: the PTV46 included the prostate and vesicles, the 
PTV70 included the prostate and the basis of the vesicles and the PTV78 included the prostate only.  
The full bladder was delineated as part of the treatment planning. Patients were instructed to urinate and 
drink half a liter of water one hour prior to radiotherapy. The bladder wall was created using an inner ring 
within the full bladder of 3.3mm (8). The trigone was defined as the triangle-shaped structure between 
the transition of the ureters in the bladder wall cranially and the transition of the urethra into the bladder 
wall caudally (9) (Figure 1). 
 
Endpoints 
Side effects were assessed prospectively using questionnaires filled out by patients treated between 2005 
and 2009. The questionnaires have been previously used in a multicenter randomized phase III trial (10) 
and at our institute (11). Using these questionnaires, the different endpoints were scored according to the 
 
Common Terminology Criteria for Adverse Events version 3.0 (CTCAE 3.0) scoring system (12). Late toxicity 
was assessed at six months, 12 months, 24 months and 36 months after treatment, finally resulting in a 
single maximum toxicity score per endpoint over the entire three years. The minimal follow up of patients 
alive was 3 years. 
Urinary incontinence grade ≥ 2 was defined as spontaneous loss of urine and when use of pads was 
indicated. Hematuria grade 1 was defined as minimal bleeding when no intervention was indicated, while 
hematuria grade 2 was defined as bleeding requiring medical intervention. Pain or discomfort during 
urinating grade 1 was defined as mild pain not interfering with function, while pain grade ≥2 was defined 
as pain interfering with instrumental activities of daily living (ADL). Finally, voiding frequency increase was 
defined as an increase of >2 times normal (grade ≥2).  
 
Statistical analysis 
The candidate prognostic factors of the four endpoints in our analysis were selected based on available 
literature on GU-NTCP modeling (4-6)  and included the mean dose for each organ at risk and the relative 
volumes receiving 5-70 Gy, in 5 Gy bins (V5-V70). Additionally, we included age, adjuvant hormonal 
treatment, and pre-treatment factors (Table 1) as candidate predictors, which were retrieved 
retrospectively from the patient charts.  
To show the crude effect of each endpoint, a univariable logistic regression analysis was performed on 
every endpoint. For the development of the multivariable prediction models the least absolute shrinkage 
and selection operator (LASSO) method in R was used, available in the Lasso and Elastic-Net Regularized 
Generalized Linear Model package, version 2.0-2 (13). This is a logistic regression analysis with a penalty 
for the magnitude of the regression coefficients to prevent overfitting (14). Because of the high collinearity 
of the candidate predictors, the set of variables was reduced prior to the LASSO analysis; from the dose 
variables that had an intercorrelation > 0.80 only the most significant predictor (as measured by the p-
value in univariable analysis) remained a candidate prognostic factor.  
Subsequently, the variables selected by LASSO were fitted again to the data with logistic regression and 
internally validated through bootstrapping. This validation gives a measure of optimism of the model, 
which can be used to correct the coefficients of the model performance accordingly. Model performance 
was described using various validation measures (15) (16). The discriminating ability of the model was 
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described by the Area Under the receiver operating characteristic Curve (AUC). Nagelkerke’s R2 was 
calculated as a pseudo measure of explained variance. The gain and intercept of the model calibration 
were calculated, and the calibration was evaluated using a Hosmer-Lemeshow test (17). Results with 
p<0.05 were considered as significant.  
Finally, for each endpoint a NTCP curve was constructed based on the corrected regression coefficients 




   (formula 1) 
Results 
Urinary incontinence 
Twenty nine out of 243 patients (12.0 %) experienced grade 2 or higher urinary incontinence. The 
candidate predictors of urinary incontinence included dosimetric predictors of all bladder structures and 
pre-treatment variables diabetes, age, cardiovascular disease, abdominal surgery, adjuvant hormonal 
treatment and TURP. Nine patients experienced grade ≥ 2 incontinence prior to radiotherapy. As these 
patients already experienced the endpoint of the model before treatment, they were excluded from the 
multivariable model on incontinence. In the univariable analysis and the V55-V75 and mean dose of the 
trigone were associated with urinary incontinence (Table 2).  
The final multivariable analysis resulted in a model with one predictor (Figure 2), i.e. the trigone mean 
dose (Confidence Interval (CI) Odds Ratio (OR): 1.02-1.20), with a corrected AUC of 0.66 (CI: 0.58-0.78) and 
a corrected R-square of 0.10 (Table 3).  
In individual cases, the risk of urinary incontinence can be estimated using formula 1, where S is defined 
as: 
 
! = −9.67 + 0.1015 ∙ (trigone	(mean)	)	 
 
 
The Hosmer-Lemeshow test was not significant (chi square of 4.91.71; degrees of freedom (df) = 8; 
p=0.77), indicating good agreement between expected and observed complication rates.  
Table 2: Univariable logistic regression analysis for urinary incontinence, hematuria and pain during voiding. 
Only p-values < 0.05 are shown. 
    Odds ratio 
(OR)* 
CI p-Value 
Urinary Incontinence ≥ grade 2 (n=20)         
Trigone Mean dose 1.11 1.02-1.20 0.015 
  V55 1.08 1.01-1.16 0.027 
  V60 1.06 1.01-1.11 0.016 
  V65 1.05 1.01-1.08 0.010 
  V70 1.03 1.01-1.05 0.008 
  V75 1.01 1.00-1.02 0.042 
          
Hematuria ≥1 (n=23)         
Cardiovascular disease   2.845 1.19-6.80 0.019 
Anticoagulants use   2.424 1.01-5.85 0.049 
Bladderwall Mean dose 1.028 1.00-1.06 0.032 
  V40 1.017 1.00-1.03 0.040 
  V45 1.019 1.00-1.04 0.024 
  V50 1.020 1.00-1.04 0.015 
  V55 1.021 1.00-1.04 0.014 
  V60 1.022 1.01-1.04 0.011 
  V65 1.024 1.01-1.04 0.007 
  V70 1.026 1.01-1.04 0.004 
  V75 1.027 1.01-1.04 0.002 
Bladder V70 1.015 1.00-1.03 0.029 
  V75 1.015 1.00-1.03 0.021 
          
Pain during voiding         
TURP   2.46 1.01-5.99 0.048 
Trigone Mean dose 1.106 1.03-1.19 0.008 
  V50 1.048 1.00-1.10 0.043 
  V55 1.047 1.01-1.09 0.024 
  V60 1.042 1.01-1.08 0.015 
  V65 1.038 1.01-1.07 0.008 
  V70 1.030 1.01-1.05 0.003 
  V75 1.021 1.01-1.03 0.001 
          
For dose variables OR: increase per 1 Gy increase in dose, for volume parameters: increase per 1% increase in 
volume 
TURP: transurethral resection of the prostate       
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Table 3: Performance and calibration measures for the multivariable model for urinary incontinence, hematuria 
and pain during voiding. Apparent measures were calculated using the complete dataset on which the model was 
trained; the corrected measures were adjusted for optimism as calculated with a bootstrapping procedure.  
Performance and    Urinary incontinence   
  
Hematuria   Pain during voiding 
calibration 
measure   
Apparent Corrected   Apparent Corrected   Apparent Corrected 
  AUC*     0.66 0.66 0.72 0.71 0.77 0.76 
  Nagelkerkes R2   0.11 0.10 0.13 0.10 0.16 0.13 
  
Discrimination 
Slope   0.04 0.04 0.08 0.08 0.08 0.08 
AUC: Area under the Curve                       
 
Hematuria 
In total, 23 out of 243 (9.5%) patients experienced grade ≥ 1 hematuria, of which 3 (1%) grade 2. Because 
of the low number of patients with grade 2 toxicity (3), we decided to use grade ≥ 1 hematuria as primary 
endpoint for this analysis. The candidate predictors for hematuria included dosimetric predictors of all 
bladder (sub)structures and other pre-treatment variables, including diabetes, age, cardiovascular disease, 
abdominal surgery, adjuvant hormonal treatment, anticoagulants and TURP.    
In the univariable analysis grade ≥ 1 hematuria was associated with the V40-V75 and mean dose of the 
bladder wall and the V70-V75 of the bladder (Table 2). In addition, significant associations were found with 
cardiovascular disease and anticoagulant use.  
The final multivariable analysis resulted in a model with two predictors (Figure 2), including the bladder 
wall V75 (CI OR 1.03-1.03) and cardiovascular disease (CI 3.12-3.31), with a corrected AUC of 0.71 (CI: 0.62-
0.84) and a corrected R-square of 0.10 (Table 3). In individual cases, the risk of hematuria can be estimated 
using formula 1, where S is defined as: 
 
 
! = −3.45 + 0.028 ∙ Lbladderwall(V75)P + 1.15 ∙ (cardiovascular	disease))	 
With bladder wall(V75) in relative volume % and cardiovascular disease is 1 (yes) or 0 (no). 
 
The Hosmer-Lemeshow test had a chi square of 4.96 (df=8, p=0.76), indicating good agreement between 
expected and observed complication rates. 
  
Pain or discomfort during voiding. 
A total number of 24 out of 243 patients (9.9%) experienced moderate discomfort or pain during voiding 
(≥ grade 2). The candidate predictors of pain or discomfort during voiding included dosimetric predictors 
of all bladder (sub)structures and a number of other pre-treatment variables including diabetes, age, 
cardiovascular disease, abdominal surgery, adjuvant hormonal treatment and TURP.   
In the univariable analysis the V50-V75, mean dose of the trigone and TURP were significantly associated 
with increased pain or discomfort during voiding (Table 2).  
The final multivariable analysis resulted in a model with two predictors (Figure 2), including TURP (CI OR 
1.18-7.83) and trigone (V75) (CI OR 1.01-1.04), with a corrected AUC of 0.76 (CI: 0.67 – 0.86) and a 
corrected R-square of 0.13 (Table 3). In individual cases, the risk of pain or discomfort during voiding can 
be estimated using formula 1, where S is defined as: 
! = −3.87 + 0.021 ∙ (trigone(V75) + 1.06	 ∙ (TURP)	 
With trigone(V75) in relative volume % and TURP is 1 (yes) or 0 (no). 
 
The Hosmer-Lemeshow test was not significant (chi square 7.84; df 8; p=0.48), indicating good agreement 
between expected and observed complication rates. 
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Increase in voiding frequency (night and day) 
In the univariable and multivariable analysis no significant associations were found for any of the 
dosimetric or pre-treatment predictors with voiding frequency.    
  
 
Figure 2: Final logistic regression analysis for urinary incontinence, hematuria and pain/discomfort 
during voiding. The left graphs represent relative volumes with corresponding NTCP risk. The right 
graphs respresent calibration plots for internal validation. The blue points represent the Hosmer–
Lemeshow groups and the dashed line represents the identity line.  
CVD: cardiovascular disease. TURP: Transurethral resection of the prostate 
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The main objective of this study was to develop multivariable NTCP models for urinary incontinence, 
hematuria, pain or discomfort during voiding and increase in voiding frequency based on different 
subregions within the bladder. Urinary incontinence was best predicted by the trigone mean dose. 
Hematuria was best predicted by the bladder wall V75 and cardiovascular disease. Pain or discomfort 
during voiding was best predicted by the trigone V75 and cardiovascular disease. No associations were 
found for increase in voiding frequency. 
Our data show that the dose to the trigone may have an impact on the occurrence of GU complaints, which 
is in line with research on patients with high-dose IMRT (86.4 Gy) (9)  and with brachytherapy (6,7). In both 
studies complaints were scored using the IPSS (International Prostate Symptom Score (IPSS)), resulting in 
a single (side effect) score for each patient. As different GU side effects have a different pathophysiology 
(18), relating each side effect individually to different dose parameters may be more appropriate and 
results in more appropriate associations between dose-volume parameters and specific side effects. 
Urinary incontinence may originate in the trigone of the bladder, as the lower part contains the involuntary 
internal or pre-prostatic sphincter (18). A decrease in dose to this region may likely decrease the incidence 
of urinary incontinence. However, the external sphincter of the bladder may also play a role in urinary 
incontinence as it controls the voluntary control of voiding. The external sphincter lies directly beneath 
the prostate and thereby receives high doses. As this structure is hard to distinguish on CT images we were 
not able to investigate the impact of dose to this region. The use of MRI in delineating target organs may 
offer better opportunities to analyze the effect of external sphincter dose-volume parameters on 
incontinence, as the external sphincter can be better identified with MRI (18).  
External beam radiotherapy can cause hematuria (19-20), which is most likely related to the high dose 
areas within the bladder (21). In the latter study the volume of the whole bladder receiving ≥ 75 Gy was 
the best predictor for hematuria. Although the univariable analysis of the present study showed similar 
results, no such relationship was found in the final multivariable model, which actually showed that the 
dose to the bladder wall was a better predictor of hematuria than the entire bladder dose. These results 
suggest that the dose to the entire bladder is a surrogate for the importance of the dose to the bladder 
wall. From a pathophysiological point of view, it seems evident that dose hotspots to the bladder wall are 
more indicative of side effects (22-23).  Anticoagulants use was significantly related to hematuria in the 
univariable analysis, which is in accordance with a study by Palorini (24). In that study, cardiovascular drugs 
 
were found as risk factors for a decreased IPSS score, indicating a possible impaired healing process of 
radiation-induced damage in patients with microangiopathic disease. Interestingly, anticoagulants were 
not significant anymore in our  multivariable model. This may be caused by the fact that a significant 
number of patients with cardiovascular disease used anticoagulants. Cardiovascular disease NTCP models 
performed better than NTCP models with anticoagulants, indicating the importance of taking into account 
cardiovascular disease in treatment of prostate cancer patients (25-26).  
The question may arise what the impact is of volume and motion of the bladder on finding dose-volume 
relations. A study by Palorini (27) on bladder motility during treatment showed that the cranial and 
anterior part of the bladder exhibits large systematic variation. The caudal part of the bladder however is 
relatively independent of bladder filling and may therefore be a reliable predictor in optimizing prostate 
radiotherapy. The trigone is a relatively rigid part of the bladder, as the bladder neck is surrounded by the 
prostate and encompassing puboprostatic ligaments (28). A study on prostatectomy shows that sparing of 
these ligaments may result in less urinary incontinence (29). Taking these results into account, the dose to 
the trigone that we found to be predictive of urinary incontinence and pain, may be a surrogate for these 
ligaments. However, these ligaments were not visible on CT and were therefore not investigated as an 
organ at risk for any of the four endpoints. 
Although increase in voiding frequency is reported frequently as a side effect resulting from prostate 
radiotherapy, we were not able to find an association between dose to different anatomical regions and 
increase in voiding frequency.  In a recent study using a pixel-wise analysis of dose-surface maps (30), a 
relation was found between the dose to the posterior bladder at 5-12 mm from the base and an acute 
increase in voiding frequency. Therefore, future research should focus on this endpoint to confirm this 
dose-volume relation in order to prevent a decrease in quality of life of prostate cancer patients.   
A limitation of this study was the low number of events for each endpoint. The internal validation showed 
that for these data the models performed relatively well and despite the low number of events the 
robustness in this dataset was relatively large (3)(31). There are different ways to analyze dose-effect 
relationships, e.g. LASSO, bootstrapping and “simple” backward regression analysis. To check the 
robustness of our analysis, all of the aforementioned procedures were tested in our data and all led to 
more or less the same results, indicating our results were relatively independent of the type of analysis 
that was used and relatively independent of the low number of events. However, external validation in 
other datasets is warranted. We are currently working on a study to validate our data externally as was 
done at our institute for head and neck cancer patients (32). 
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Another limitation of this study is the variability of the bladder volume during treatment. Research has 
shown that patient motion, bladder centroid motion and bladder filling may have an impact on 
pretreatment imaging (33). We recommend researchers to take this into account in future studies on 
prostate NTCP-modeling by using daily imaging techniques and deformable image registration.   
 
This study shows that different anatomical subregions within the bladder are related to different side 
effects. Urinary incontinence and pain during voiding is related to dose to the trigone and hematuria is 
related to the dose in the bladder wall. This information can be used in treatment plan optimization. 
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Chapter 6: Summarizing discussion and future perspectives 
 
Introduction 
This thesis was performed to investigate the course of quality of life among prostate cancer patients 
treated with radiotherapy, to investigate which side effects have the largest impact on quality of life and 
ultimately to develop multivariable NTCP-models for prostate cancer patients treated with definitive 
radiotherapy.  
Summary of main findings 
In chapter 2 the difference in quality of life between prostate cancer survivors and a normative cohort of 
men was analysed. In this longitudinal case-control study, we showed that the quality of life of patients 
after radiotherapy is declined as compared to their quality of life before treatment and as compared to 
the normative cohort. Additional analyses showed that co-morbidity such as coronary heart disease and 
COPD have an influence on the course of this decline.  
In chapter 3 we investigated possible causes for the decline in quality of life after radiotherapy. In this 
study, using a multivariate approach, the relationship between different side effects and quality of life was 
presented. Both gastrointestinal and genitourinary toxicity had a significant impact on the quality of life of 
patients after completion of the treatment.  
Chapter 4 shows the relationship between different dose volume parameters within and around the 
anorectum and gastrointestinal side effects. Different anorectal side effects were associated with different 
anatomical substructures; rectal bleeding was associated with high doses to the anorectum and 
anticoagulants use, anal incontinence was associated with the dose levels to the external anal sphincter 
and iliococcygeal muscle. Finally, stool frequency was associated with intermediate doses to the levator 
ani muscles. 
In chapter 5 dose volume parameters of the bladder were related to genitourinary side effects. Different 
urinary side effects were associated with different anatomical substructures within the bladder; urinary 
incontinence was associated with the mean dose to the trigone, while haematuria was associated with 
high doses to the bladder wall and with cardiovascular disease. Finally pain during voiding was associated 
with high doses to the trigone and a history of TURP.   
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The life expectancy of patients with localized or locally advanced prostate cancer is relatively favourable 
in comparison with that of patients with other cancer types. In recent decades, the introduction of 
radiation dose escalation in prostate cancer has resulted in a 10-year PSA relapse-free survival of 84% [1]. 
Considering this relatively good prognosis, other endpoints of (radio)therapy have become more 
important in the selection process of the different treatment options. In radiotherapy, genitourinary and 
gastrointestinal side effects are commonly reported by prostate cancer patients [2, 3]. However, limited 
data existed on the impact of these side effects on patients’ quality of life. Prevention of these side effects 
is particularly important when patients’ quality of life is negatively affected. Therefore, it is essential to 
gain more information about the extent to which dose-volume parameters are associated with radiation-
induced toxicities [4, 5]. The relationship between radiation dose to specific anatomical structures and the 
probability of developing certain side effects can be described by so-called Normal Tissue Complication 
Probability (NTCP) models. Accurate prediction of the risks of radiation-induced side effects may offer 
opportunities to optimize dose distributions to minimize radiation-induced side effects, to select the best 
technique and to identify patients that will benefit most from new radiation delivery techniques, such as 
protons, which were introduced in the Netherlands in 2018.    
 
Quality of life of prostate cancer patients before and after radiotherapy 
The interpretation of the impact of an improvement or deterioration in quality of life during a patients’ 
life is often difficult without a clear normative benchmark. Therefore, in this thesis, we compared the 
quality of life of a normative group of men with that of prostate cancer patients treated with radiotherapy 
(Chapter 2).  Our study showed that, considering possible (in)equality at baseline, quality of life of patients 
is only minimally impaired as compared to the normative group and as compared to baseline regarding 
the general aspects of daily functioning. This may imply that prostate cancer radiotherapy is relatively well 
endured by patients. However, several aspects such as social and role functioning may deteriorate and 
require special attention. To investigate the possible causes for this decline it is essential to know which 
and to what extent toxicity endpoints affect patients’ quality of life. Traditionally, rectal bleeding is 
regarded as the most important side effect in prostate radiotherapy, which is reflected by the number of 
studies on this topic [6][7][8][9][10][11][12]. Although severe rectal bleeding is clinically relevant, mild or 
moderate urinary incontinence and rectal discomfort may influence a patient’s quality of life more than 
 
rectal bleeding (Chapter 3). Therefore, next to attention to rectal bleeding, more attention is needed on 
the prevention of urinary incontinence and rectal discomfort as well. 
 
Gastrointestinal side effects 
Predicting gastrointestinal side effects by means of NTCP models requires a clear definition of the organs 
at risk (OAR) and a clear definition of endpoints. The anorectum may be divided in a lower (anal) and upper 
(rectum) part [9, 10]. Analyses on dose to other substructures such as the anterior rectal wall present 
interesting dose effect relations [11]. Additionally, Smeenk et al. found significant dose-effect relationships 
between the pelvic floor muscles with faecal incontinence and high stool frequency [12].  
The anorectum is encompassed by a wide variety of muscles and defecation is a complex activity controlled 
by voluntary and involuntary sphincters around the anus. Taking into account this relatively complex 
activity, the question arises which of these potential OAR’s is most important for the development of 
radiation-induced gastrointestinal side effects and if radiotherapy treatment planning can be optimized if 
the dose is minimized in specific substructures within or around the anorectum. Given the aforementioned 
studies on dose effect relationships and the theoretical basis for late anorectal dysfunction [13], we 
decided to not only consider the most frequently investigated composed OAR’s, but also to investigate the 
relationship between the doses to different muscles around the anorectum and the risk on gastrointestinal 
side effects, in particular with regard to anal incontinence (Chapter 4). 
All investigated predictors, both “traditional” and “new”, performed relatively well in our analysis. The 
prognostic significance of the traditional predictor, i.e. the dose to the anorectum was confirmed in the 
univariable analysis on rectal bleeding with higher doses to the anorectum resulting in higher probabilities 
of developing grade ≥ 2 rectal bleeding. Dosimetrics of more detailed substructures, such as of the rectal 
wall, the anus or rectum, were less predictive of rectal bleeding, in terms of model performance. 
In contrast, faecal incontinence and high stool frequency showed a better performance for the dose to the 
substructures than the dose to the composed larger OAR’s. The multivariable analysis showed that a 
particular subset of the pelvic floor muscles, i.e., the iliococcygeal muscle, the levator ani muscle and the 
external sphincter, were significantly associated with these two endpoints. These pelvic floor muscles join 
at different places and work together to support the pelvic viscera and to maintain faecal continence [14, 
15]. The majority of (midrange) pelvic floor dose parameters were associated with these endpoints in the 
univariable model, in line with the results found by Smeenk, et al. [12]. Given the close anatomical and 
functional relationship, we cannot rule out the influence of dose to one of the pelvic floor muscles, such 
as the puborectal muscle and internal sphincter, which were ultimately not included in the final model.  
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We were not able to find associations between dose to structures within or around the anorectum and 
rectal pain. Comparable results were found in the RADAR (Randomised Androgen Deprivation and 
Radiotherapy) [16] trial. Recently, Cicetti [17] found an impact of midrange dose volume factors on stool 
frequency and rectal pain. The inclusion of a large sample of patients (n=1336) and the use of a different 
toxicity scoring system (i.e. Late Effects of Normal Tissue/Subjective, Objective, Management and Analytic: 
LENT/SOMA scale) may explain the different outcomes among these studies [18,19].  
The models presented in our final analyses are all highly stable in the internal validation, but they should 
be interpreted with some caution. The dose to the pelvic floor muscles has a clear impact on faecal 
incontinence and high stool frequency, but an external validation study is required to confirm the relatively 
simple models presented in our final analysis.  
Given the shape of the dose response curve of the NTCP-model presented, patients with a high  V70 to the 
anorectum may particularly benefit from planned dose optimisation as compared to patients with an 





          
            
            
            
            
            
            
            
            
 
Figure 1: NTCP rectal bleeding reduction with 5% decrease in dose to the V70 of the anorectum. Blue 
represents a patient with an expected NTCP reduction of 40%. Yellow represents a patient with an 
expected NTCP reduction of 10%.   
Altering radiotherapy treatment planning guided by NTCP models may result in a marked reduction in 
treatment related side effects. However, complete prevention of side effects is not awaited and therefore 
other treatment options in relation to side effects require extra attention. Treatment options for patients 
 
with grade ≥ 2 rectal bleeding may involve steroid enemas and one or more argon plasma coagulations 
(APC) and these are generally regarded as effective and are widely used after diagnosis of radiation 
induced rectal bleeding [20]. Treatment of faecal incontinence and high stool frequency after radiotherapy 
is less evident in clinical practice. A review on pelvic floor muscle training and biofeedback therapy showed 
a positive effect for most patients with any kind of faecal incontinence [21]. In this way, the continuation 
of faecal incontinence after prostate radiotherapy could be halted or decreased. Rectal pain may be 
countered by means of medicines such as analgesia and amifostine [22] More recently, synbiotics have 
also been shown to improve quality of life after prostate cancer radiotherapy [23].         
 
Genitourinary side effects  
Genitourinary side effects are less under investigation in comparison with gastrointestinal side effects [8]. 
An explanation might be that, due to bladder volume variability, an estimation of the actual given dose is 
difficult [24]. Despite these difficulties, significant relationships were found between the dose to specific 
structures within the bladder and genitourinary side effects in patients treated with brachytherapy [25]. 
However, limited data exist on equivalent relationships after external beam radiotherapy. One study, in 
patients treated with 48 fractions of 1.8 Gy to a total dose of 86.4 Gy, showed [26] a significant relationship 
between the dose to the lower parts of the bladder and genitourinary side effects. In our study (Chapter 
5), for patients treated in 39 fractions to a total dose of 78 Gy we found comparable effects; the dose to 
the trigonum was predictive for incontinence and pain during urinating.  
Based on the significant impact of urinary incontinence on the more general dimensions of quality of life 
as found in our study (Chapter 3), this side effect deserves more attention. 
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Figure 2: NTCP urinary incontinence reduction with 10 Gy decrease in mean dose to the trigonum (75Gy -
> 65Gy). An NTCP reduction of 0.06 is possible for this patient. 
Additionally, we found an impact of bladder wall dose on haematuria comparable with studies by Ahmed 
[27] and Harsiola [28].  Although it is theoretically possible to decrease the dose to different bladder 
structures (figure 2) the practicability is questionable. The trigonum is in close vicinity to the prostate and 
consequently it may be difficult to prevent delivery of radiation to this substructure. This problem may be 
countered by proton therapy, which offers the opportunity to deliver most of its energy at a certain depth. 
Planning studies by Scobioala [29] and Yeo [30] showed that proton therapy decreased a range of dose 
variables to the entire bladder compared to photon therapy. Evidence on more specific substructures as 
analysed in our study are lacking in current prostate cancer literature. 
The mobility of the bladder and the variation in bladder filling are another challenge in prostate cancer 
radiotherapy. Fluid intake prior to radiotherapy is often applied, as it causes a comparable anatomy to 
planning. A study by Palorini [31] on bladder motility during treatment showed that the cranial and 
anterior part of the bladder exhibits large systematic variation. The caudal part of the bladder, however, 
is relatively independent of bladder filling and may therefore be a reliable substructure in optimizing 
prostate radiotherapy [32].   
Although our aim was to identify structures that cause genitourinary toxicity, we did not investigate the 
impact of dose to penile structures/neurovascular bundle/vascular structures on impotence or orgasmic 
dysfunction. Impotence and orgasmic dysfunction are part of a patient’s sexual functioning and have an 
impact on their and their partner’s quality of life after prostate radiotherapy [33].  Recent studies [34, 35] 
show that dose to the corpus cavernosum, the penile bulb and the total penile structure are predictive of 
a decreased sexual functioning after radiotherapy. Proton therapy may decrease the dose to the penile 
structures and may thereby offer the opportunity to even further enhance a patients’ quality of life after 
radiotherapy.  
 
Conclusions and future perspectives 
This thesis is the first important step of the model-based approach in curative prostate cancer treatment 
[4]; i.e., which patients will benefit most from organ at risk sparing? The NTCP-models on gastrointestinal 
and genitourinary side effects showed high model performance and suggested that a decrease in dose to 
specific substructures of the organs at risk may result in a clinically relevant decrease in complication 
probability. This information is important, given the trend in hypofractionation and the introduction of 
proton therapy in the Netherlands and around the world. However, external validation in independent 
 
cohorts of prostate cancer patients is warranted [36]. In addition, an estimation of the practicability of the 
given models in an in silico planning comparative study (ISPC) should be performed before introducing 
these models in practice or into new radiation delivery techniques. Part of the (sub) structures under 
investigation in our study were analysed in the same way by Scobioala and Yeo; Protons offer the 
opportunity to reduce dose to the anorectum and bladder wall with preservation of a homogeneous and 
highly conformal dose distribution [29] [30].  A study by Schwarz [37] showed that 5 field IMPT (Intensity 
modulated proton therapy) resulted in a reduction of more than 50% to the V70 of the rectum. The last 
step in determining model-based indications for new delivery techniques is the estimation of the clinical 
benefit of these models. This has not been investigated in the current literature and should be investigated 
in future research.   
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Conclusions and future perspectives 
This thesis is the first important step of the model-based approach in curative prostate cancer treatment 
[4]; i.e., which patients will benefit most from organ at risk sparing? The NTCP-models on gastrointestinal 
and genitourinary side effects showed high model performance and suggested that a decrease in dose to 
specific substructures of the organs at risk may result in a clinically relevant decrease in complication 
probability. This information is important, given the trend in hypofractionation and the introduction of 
proton therapy in the Netherlands and around the world. However, external validation in independent 
 
cohorts of prostate cancer patients is warranted [36]. In addition, an estimation of the practicability of the 
given models in an in silico planning comparative study (ISPC) should be performed before introducing 
these models in practice or into new radiation delivery techniques. Part of the (sub) structures under 
investigation in our study were analysed in the same way by Scobioala and Yeo; Protons offer the 
opportunity to reduce dose to the anorectum and bladder wall with preservation of a homogeneous and 
highly conformal dose distribution [29] [30].  A study by Schwarz [37] showed that 5 field IMPT (Intensity 
modulated proton therapy) resulted in a reduction of more than 50% to the V70 of the rectum. The last 
step in determining model-based indications for new delivery techniques is the estimation of the clinical 
benefit of these models. This has not been investigated in the current literature and should be investigated 
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In dit proefschrift wordt allereerst het verloop van de kwaliteit van leven van prostaatkankerpatiënten die 
behandeld worden met radiotherapie onderzocht. Daarnaast is onderzocht welke bijwerkingen de 
grootste impact hebben op de kwaliteit van leven en als laatste zijn twee NTCP modellen gemaakt om de 
kans op bijwerkingen op basis van dosis te voorspellen.  
Belangrijkste bevindingen 
In hoofdstuk 2 wordt het verschil in kwaliteit van leven tussen prostaatkankerpatënten en een normatief 
cohort onderzocht. In deze longitudinale case-control studie tonen we aan dat de kwaliteit van leven van 
patiënten behandeld met radiotherapie lager is dan voorafgaand aan de behandeling en lager dan de 
kwaliteit van leven van het normatieve cohort. Aanvullende analyses lieten zien dat comobiditeit zoals 
hartaandoeningen en COPD een invloed hebben op het verloop van deze afname.  
In hoofdstuk 3 zijn de mogelijke oorzaken voor de afname in kwaliteit van leven na radiotherapie 
onderzocht. De impact van bijwerkingen op de kwaliteit van leven is geanalyseerd gebruikmakend van een 
multivariate analyse. Zowel gastrointestinale als genitourinaire toxiciteit hadden een significante invloed 
op de kwaliteit van leven van deze patiënten na afloop van hun behandeling.  
In hoofdstuk 4 is de relatie bepaald tussen gastrointestinale klachten en dosisvolume parameters in en 
direct rondom het anorectum. Verschillende klachten waren geassocieerd aan verschillende anatomische 
substructuren; rectaal bloedverlies was gerelateerd aan hoge dosis aan het anorectum als geheel en 
bloedverdunners, incontinentie was gerelateerd aan de dosis aan de externe anale sfincter en musculus 
iliococcygeus. Defecatie frequentie was gerelateerd aan intermediaire doses aan de musculus levator ani. 
In hoofdstuk 5  zijn de dosis-volume paramters van de blaas gerelateerd aan genitourinaire klachten.  
Verschillende bijwerkingen waren geassocieerd met verschillende anatomische substructure in de blaas; 
incontinentie voor urine was geassocieerd aan de gemiddelde dosis aan het trigonum, terwijl haematurie 
gerelateerd was aan de dosis aan de blaaswand en hartaandoeningen. Dysurie was gerelateerd aan hoge 
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moesten tekenen en welke niet. Je ambitie om mij dat in mijn promotietraject goed te laten uitzoeken 
heeft mede tot dit proefschrift geleid. Op persoonlijk vlak hebben we beiden veel meegemaakt de laatste 
jaren, iets wat we met elkaar konden delen op een collegiale en soms vriendschappelijke manier. Dat heeft 
ons contact versterkt, ook op inhoudelijk vlak.  
Beste Cees,  een psycholoog die een model wil maken voor dosis en kans op bijwerkingen. Je had daar in 
het begin van mijn promotietraject je twijfels over. Ook al was je meer op de achtergrond aanwezig als 
promotor, de overleggen die we hadden, met name aan het begin van het promotietraject,  gaven mij 
moed. Je was immer positief en was erg enthousiast over mijn bevindingen. Erg leuk was het toen we 
samen in een andere rol gingen samenwerken, binnen de Hanze Ethisch Advies Commissie. Daar heb ik 
geleerd dat pragmatisch zijn (jij) niet per sé recht tegenover afstappen van principes (ook jij) staan. Ik 
waardeer je stimulerende bijdrage in dit proefschrift ten zeerste!  
Lieve Ada, hoe bijzonder was het begin van ons contact. Je bood me een baan als docent aan en vanaf het 
begin was het duidelijk dat we op één lijn zaten. Later werd dit een promotietraject en we weten beiden 
hoe lastig ik dat soms ervaren heb. We hebben daarover gesprekken gehad, soms moeilijk, maar je wist 
me toch op de één of andere manier te stimuleren door te gaan. Ik ben je daarvoor heel dankbaar, je 
motiverende houding heeft me mede gebracht tot dit proefschrift. Leuk dat je ook, terwijl je al even met 
pensioen bent, aanwezig bent bij de ceremonie samen met Wim! 
Alle collega’s van de MBRT wil ik bedanken voor hun interesse in mijn onderzoek. Met name de RT-
vakgroep, Esther, Ruth, Remco, Jordy en Age waren altijd geïnteresseerd in welk model ik nu weer 
opgesteld had om bijwerkingen te voorspellen. Erg mooi ook dat er uiteindelijk een speciaal onderdeel 
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Daarnaast wil ik Hendrik en Annemieke speciaal bedanken. Hendrik, de broodjes Ben en uitstapjes naar 
de Jumbo waren, zeker in de tijd dat het privé wat lastiger was, rustgevend. Ik dank je voor je immer 
luisterend oor. Annemieke, het zijn van AFP docent, MHAP docent en inmiddels MPA docent bond ons op 
collegiaal vlak, maar de humor, soms enigszins cynisch over het vak als docent en als promovendus (ja je 
was al in een ver verleden gepromoveerd)  gaf extra cachet aan deze band. Wij weten beiden als geen 
ander dat dit proefschrift is opgemaakt zonder pigeon holing, toch? Hendrik en Annemieke, ik hoop met 
jullie beiden nog lang samen te werken bij de MBRT! 
De onderzoekers uit de onderzoeksruimte RT. Vikram, Miranda, Enja, Agata, Kim, Paul, Sanne en 
natuurlijk Zwaanette. De lunches in de Brug, met de heerlijke “brug-tosti’s” deden mij altijd goed. Samen 
als onderzoekers de ervaringen delen over het onderzoek, maar vooral ook de ins en outs van de promoter 
en copromoteren bespreken deed me goed. Een speciaal woord voor Zwaanette en Sanne: Lieve 
Zwaannette, je interesse in alles wat mij bezig hield, en ja ook echt alles (je weet wel wat) maakt jou een 
mooi persoon, ik merk dat ik je de laatste tijd al weer veel te weinig gesproken heb! Kan ik binnenkort 
eens een keertje langskomen om jouw Tom nu eindelijk eens te bewonderen? Lieve Sanne, slappe grappen 
en “ik schrijf daar wel even een scriptje voor”, zo herinner ik me jou vooral. Je hulp bij het “extracten” van 
de dosis uit de DVH data was onmisbaar. Uiteindelijk heb je me ingehaald met promoveren, ik verwacht 
dat jij zeer binnenkort professor van Dijk bent en dat is je gegund! 
Arjen van der Schaaf. “Ik run wel even het script met deze selectie van de variabelen”. Die zin hebben we 
vaak besproken. Daar waar je me hebt laten zien hoe in Matlab een door bootstrapping gecorrigeerd 
model theoretisch gezien werkt, heb ik zelf in R laten zien dat ik dat ook kan. Dat laatste was niet mogelijk 
geweest zonder jouw soms (maar zeker niet altijd) relatief eenvoudige weergave van ingewikkelde 
wiskundige modellen. Als we kijken naar mijn onderzoek, durf ik met 95% betrouwbaarheid te zeggen, dat 
ondanks dat we relatief weinig besprekingen hebben gehad,  de richtingscoefficiënt van mijn leercurve 
tijdens deze meetings met jou het stijlst was, heel veel dank daarvoor! 
Martijn, je bent alweer een tijdje bezig met je passie op het gebied van onderzoek bij het Reshape Center 
van het Radboud. In de eerste jaren van mijn promotie-onderzoek was je onmisbaar. De manier om dingen 
op te schrijven en te kijken naar wat belangrijk is en vooral wat niet (kill your darlings!). Dank voor de 
immer motiverende woorden en je altijd positieve blik op mijn promotie-onderzoek. Het ga je goed in 
Nijmegen!  
Hans Paul. Het begon als kamergenoten, maar uiteindelijk hebben we toch vele “hobby’s” gedeeld, 
waarbij jij over het algemeen iets intensiever betrokken was dan ik. Vage gesprekken over statistiek, 
squash, goede koffie zetten en geocaching waren gemeenschappelijke interesses, waarin jij soms iets 
beter was dan ik en andersom (ik ben inmiddels alweer vergeten hoeveel gram je van welke boon je ook 
weer moest nemen voor de perfecte espresso, kun je me binnenkort weer even bijpraten over de nieuwste 
ontwikkelingen?). Ik ga ervan uit en hoop je nog vaak te mogen spreken over al bovenstaande! 
Beste Ruurd, het was altijd een wedstrijdje, wie zou eerder gaan promoveren, jij of ik? Je hebt dit dik 
gewonnen, mijn complimenten en dat voor een Fries. Onze gemeenschappelijke ervaringen als 
promovendus en docent leverde onder het genot van een lekkere chocolademelk in de kantine van de RT 
mooie gesprekken op. Vooral gedeelde frustraties en het tegelijkertijd ouder worden zorgde voor een 
 
relativering van mijn beslommeringen en voor een band voor het leven! Het was dan ook niet verrassend 
dat ik jouw paranimf was en andersom geldt hetzelfde. Sa ist en net oars, want as ’t oars wie, wie t net sa! 
Lieve mam en pap, hier ligt het voor jullie. Een proefschrift waar ik zo lang voor gewerkt heb. Iets langer 
erover gedaan dan pap, maar desalniettemin ligt het er. Ik ben er trots op en die trotsheid was er niet 
geweest zonder jullie. Jullie immer stimulerende woorden hebben mij hierin geholpen, ook in mijn 
persoonlijke leven, waar het de laatste tijd niet altijd even makkelijk was. Jullie kunnen dit proefschrift ook 
beschouwen als een product van jullie, want zonder jullie had het er niet gelegen. Ik wil jullie heel erg 
bedanken voor mijn mooie jeugd en jullie prestatiebevorderende woorden. Dikke kus! 
 
Lieve Karin, je zit helaas helemaal aan de andere kant van de oceaan te genieten van de zon in Los Angeles. 
Ik kon altijd op je rekenen als grote zus. Je hielp me vooral de afgelopen maanden via facetime een 
moeilijke periode door te komen. Heel veel dank daarvoor! Ook al is de fysieke afstand groter dan toen je 
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Liefste Maartje. Dat ik jou nog zou ontmoeten in het leven. Ik ben zo blij dat ik je heb leren keren. Je 
relativerende blik op zaken en je manier om soms met dingen om te gaan en niet teveel na te denken 
“klaar!!”. Ik hoop dat we nog heel veel mooie tijden samen hebben, met onze prachtige vier kinderen! 
Lieve Tom en Hugo. Jullie zijn voor mij de belangrijkste bron van inspiratie. Kunnen genieten van een 
torretje of een blaadje aan de boom. Jullie zijn zo mindful, ik wou dat ik nog zo was. Heel mooi dat jullie 
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dat ik jouw paranimf was en andersom geldt hetzelfde. Sa ist en net oars, want as ’t oars wie, wie t net sa! 
Lieve mam en pap, hier ligt het voor jullie. Een proefschrift waar ik zo lang voor gewerkt heb. Iets langer 
erover gedaan dan pap, maar desalniettemin ligt het er. Ik ben er trots op en die trotsheid was er niet 
geweest zonder jullie. Jullie immer stimulerende woorden hebben mij hierin geholpen, ook in mijn 
persoonlijke leven, waar het de laatste tijd niet altijd even makkelijk was. Jullie kunnen dit proefschrift ook 
beschouwen als een product van jullie, want zonder jullie had het er niet gelegen. Ik wil jullie heel erg 
bedanken voor mijn mooie jeugd en jullie prestatiebevorderende woorden. Dikke kus! 
 
Lieve Karin, je zit helaas helemaal aan de andere kant van de oceaan te genieten van de zon in Los Angeles. 
Ik kon altijd op je rekenen als grote zus. Je hielp me vooral de afgelopen maanden via facetime een 
moeilijke periode door te komen. Heel veel dank daarvoor! Ook al is de fysieke afstand groter dan toen je 
nog in Amsterdam woonde, we hebben elkaar pas écht leren kennen op het mentale vlak in de laatste 
jaren. Ik hoop je snel weer in levende lijve te zien, samen met Lucas, Isa en Onye! 
Liefste Maartje. Dat ik jou nog zou ontmoeten in het leven. Ik ben zo blij dat ik je heb leren keren. Je 
relativerende blik op zaken en je manier om soms met dingen om te gaan en niet teveel na te denken 
“klaar!!”. Ik hoop dat we nog heel veel mooie tijden samen hebben, met onze prachtige vier kinderen! 
Lieve Tom en Hugo. Jullie zijn voor mij de belangrijkste bron van inspiratie. Kunnen genieten van een 
torretje of een blaadje aan de boom. Jullie zijn zo mindful, ik wou dat ik nog zo was. Heel mooi dat jullie 




Daarnaast wil ik Hendrik en Annemieke speciaal bedanken. Hendrik, de broodjes Ben en uitstapjes naar 
de Jumbo waren, zeker in de tijd dat het privé wat lastiger was, rustgevend. Ik dank je voor je immer 
luisterend oor. Annemieke, het zijn van AFP docent, MHAP docent en inmiddels MPA docent bond ons op 
collegiaal vlak, maar de humor, soms enigszins cynisch over het vak als docent en als promovendus (ja je 
was al in een ver verleden gepromoveerd)  gaf extra cachet aan deze band. Wij weten beiden als geen 
ander dat dit proefschrift is opgemaakt zonder pigeon holing, toch? Hendrik en Annemieke, ik hoop met 
jullie beiden nog lang samen te werken bij de MBRT! 
De onderzoekers uit de onderzoeksruimte RT. Vikram, Miranda, Enja, Agata, Kim, Paul, Sanne en 
natuurlijk Zwaanette. De lunches in de Brug, met de heerlijke “brug-tosti’s” deden mij altijd goed. Samen 
als onderzoekers de ervaringen delen over het onderzoek, maar vooral ook de ins en outs van de promoter 
en copromoteren bespreken deed me goed. Een speciaal woord voor Zwaanette en Sanne: Lieve 
Zwaannette, je interesse in alles wat mij bezig hield, en ja ook echt alles (je weet wel wat) maakt jou een 
mooi persoon, ik merk dat ik je de laatste tijd al weer veel te weinig gesproken heb! Kan ik binnenkort 
eens een keertje langskomen om jouw Tom nu eindelijk eens te bewonderen? Lieve Sanne, slappe grappen 
en “ik schrijf daar wel even een scriptje voor”, zo herinner ik me jou vooral. Je hulp bij het “extracten” van 
de dosis uit de DVH data was onmisbaar. Uiteindelijk heb je me ingehaald met promoveren, ik verwacht 
dat jij zeer binnenkort professor van Dijk bent en dat is je gegund! 
Arjen van der Schaaf. “Ik run wel even het script met deze selectie van de variabelen”. Die zin hebben we 
vaak besproken. Daar waar je me hebt laten zien hoe in Matlab een door bootstrapping gecorrigeerd 
model theoretisch gezien werkt, heb ik zelf in R laten zien dat ik dat ook kan. Dat laatste was niet mogelijk 
geweest zonder jouw soms (maar zeker niet altijd) relatief eenvoudige weergave van ingewikkelde 
wiskundige modellen. Als we kijken naar mijn onderzoek, durf ik met 95% betrouwbaarheid te zeggen, dat 
ondanks dat we relatief weinig besprekingen hebben gehad,  de richtingscoefficiënt van mijn leercurve 
tijdens deze meetings met jou het stijlst was, heel veel dank daarvoor! 
Martijn, je bent alweer een tijdje bezig met je passie op het gebied van onderzoek bij het Reshape Center 
van het Radboud. In de eerste jaren van mijn promotie-onderzoek was je onmisbaar. De manier om dingen 
op te schrijven en te kijken naar wat belangrijk is en vooral wat niet (kill your darlings!). Dank voor de 
immer motiverende woorden en je altijd positieve blik op mijn promotie-onderzoek. Het ga je goed in 
Nijmegen!  
Hans Paul. Het begon als kamergenoten, maar uiteindelijk hebben we toch vele “hobby’s” gedeeld, 
waarbij jij over het algemeen iets intensiever betrokken was dan ik. Vage gesprekken over statistiek, 
squash, goede koffie zetten en geocaching waren gemeenschappelijke interesses, waarin jij soms iets 
beter was dan ik en andersom (ik ben inmiddels alweer vergeten hoeveel gram je van welke boon je ook 
weer moest nemen voor de perfecte espresso, kun je me binnenkort weer even bijpraten over de nieuwste 
ontwikkelingen?). Ik ga ervan uit en hoop je nog vaak te mogen spreken over al bovenstaande! 
Beste Ruurd, het was altijd een wedstrijdje, wie zou eerder gaan promoveren, jij of ik? Je hebt dit dik 
gewonnen, mijn complimenten en dat voor een Fries. Onze gemeenschappelijke ervaringen als 
promovendus en docent leverde onder het genot van een lekkere chocolademelk in de kantine van de RT 
mooie gesprekken op. Vooral gedeelde frustraties en het tegelijkertijd ouder worden zorgde voor een 
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